We have a brand new profile that just IPO’d on Wednesday that we wanted to bring to your attention for Friday’s session.
Pull up IVP Immediately.
The U.S. pet industry generated $103B in 2020. In 2017 there were 28,000+ pet hospitals in the U.S.
Inspire is an owner of general practice veterinary clinics in the United States. Inspire acquires practices, and, in many cases real estate, and then works with teams on a long- term basis to improve and maintain hospital operations, grow revenues and maximize earnings. As the Company expands, it is adding new services hospitals, including mixed animal facilities, critical and emergency care, and other specialty services such as equine, in one location.
THE NEAR FUTURE
The 5-year plan includes a 10 location per year run rate for acquisitions and a public event within that timeframe which allows Inspire to share equity with all associates working in its locations.
DIFFERENTIATORS
Key relationships from the acquisition process through operations and the unique position of a publicly-traded veterinary services organization, provide us advantages in growth capability,
WHAT IS INSPIRE, WHAT IS THE 5 YEAR PLAN?
Key relationships from the acquisition process through operations and the unique position of a publicly-traded veterinary services organization, provide us advantages in growth capability,befficiency and employee retention.
NEWS
INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES PRICING OF $6.4 MILLION INITIAL PUBLIC OFFERING AND NASDAQ LISTING
VIRGINIA BEACH, VA / ACCESSWIRE / August 29, 2023 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the US, today announced the pricing of its initial public offering of 1,600,000 shares of common stock at a public offering price of $4.00 per share for aggregate gross proceeds of approximately $6.4 million, prior to deducting underwriting discounts, commissions, and other offering expenses.
In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 15% of shares of common stock at the initial public offering price, less underwriting discounts and commissions to cover over-allotments, if any. The offering is expected to close on August 31, 2023, subject to customary closing conditions.
In connection with the offering, Inspire has received approval to list its shares of common stock on the Nasdaq Capital Market, with the shares expected to begin trading on August 30, 2023 under the symbol “IVP”.
Inspire expects to use the net proceeds from the offering primarily to fund the development of new products and improvements to existing products; expand sales and marketing capabilities; and for general corporate purposes, including capital expenditures and working capital.
Spartan Capital Securities, LLC is acting as sole book-running manager for the offering.
A registration statement on Form S-1, as amended (File No. 333-271198), was filed with the Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on August 29, 2023. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from Spartan Capital Securities, LLC, 45 Broadway, New York, NY 10006, or by telephone at (877) 772-7818.
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY AMPLIFYIR LLC FOR A ONE DAY IVP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
NLS Pharmaceutics today announced that the U.S. Food and Drug Administration (FDA) has reviewed the full protocol for the NLS-1031 study, part of the Phase 3 program for Mazindol ER, called AMAZE.
We are extremely excited to bring you this next one profile.
We just had you take a look at this one back in July where it ran all the to 1.11 after closing at .83 the session before we released our profile on the company.
Right now it is sitting back in the .90 range and has a smaller float of just over 14 Million.
Pull up NLSP right away.
NLSP is a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs.
CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance abuse disorders. Their discovery platform currently focuses on single molecules that function through multiple mechanisms designed to target the complexity of the CNS disease state. They believe that this approach may potentially offer new treatment options for patients, including those who are refractory to currently available treatments. Their current focus is in the therapeutic areas of rare hypersomnia disorders (conditions characterized by excessive daytime sleepiness, or EDS, such as narcolepsy) and complex neurodevelopmental disorders. Their drug development pipeline features our lead product candidate, Quilience®, for the treatment of EDS and cataplexy associated with narcolepsy, and our follow-on drug candidate Nolazol®, for the treatment of ADHD.
The MAJOR Catalyst comes in the form of an update from the CEO released on Monday.
There were two catalysts in this release that caught my eye:
First, this caught my eye: “At this time we have received several non-binding term sheets for a potential partnership agreement within the pharmaceutical industry. The Company is still in negotiations, has not executed a definitive agreement, and no party is under any obligation to enter into or continue negotiations regarding a definitive agreement related to any transaction.” This means that they have several companies that are looking to partner with them for their Phase 3 trials after looking at the initial data. This could be a good sign for the company moving forward.
Also, In the article it stated: “OnAugust 25, 2023, NLS submitted a fast-track designation application for Mazindol ER for the treatment of narcolepsy to the FDA. Fast track is a designation by the FDA of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need. A drug may be granted Fast Track Designation if it is believed to have an impact on patient survival, day-to-day functioning, or if it is believed that the condition will progress in severity if left untreated. Standard reviews by the FDA for drug approval generally take about one year. A medicine that receives Fast Track Designation can be on the market within six months of the regulatory application.” This could be huge for the company. “Fast Track” has the potential to be on the market as fast as 6 months.
Read the full release here:
NLS PHARMACEUTICS CEO ISSUES LETTER TO SHAREHOLDERS
ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:
NLS Pharmaceutics CEO Issues Letter to Shareholders
To our Shareholders and Friends,
Though we may have been quiet recently, I wanted to assure you that the team here at NLS has been very busy behind the scenes ensuring that we realize our vision of awakening a brighter future for patients. Your investment and support to advance our pipeline in rare sleep disorders and other rare and debilitating Central Nervous System (CNS) disorders is our driving force as we put patients first to develop better therapies to safeguard and empower the brain throughout all stages of life. I am pleased to report on the progress that we have made towards achieving both our short and our long-term goals.
At the outset of 2023, we outlined a number of objectives including:
Continuing to build an organization dedicated to rare and complex CNS disorders
Solidifying the opportunity for lead product Mazindol ER’s success through a rigorous Phase 3 program
Realizing Mazindol ER’s full potential across a variety of rare sleep disorders
Progressing pipeline of innovative products to meet the unmet needs of patients and transforming the lives of patients with rare diseases
In addition to making significant progress on our objectives, we have advanced in our overall efforts by participating in global medical conferences, building investor relations and partaking in discussions regarding promising opportunities. As we are at the precipice of beginning our Phase 3 program for Mazindol ER, I wanted to take the opportunity to share the promises that we have kept and the advances that we have made, which we could not have achieved without your help.
Financing
In late 2022, we completed a $10 million private placement with BVF Partners L.P., a prestigious life sciences investor. The offering and shared vision reinforced our confidence in our development program, which has the potential to benefit more than three million people across the globe challenged with narcolepsy.
We are now in the process of assessing different options to initiate our Phase 3 program as well as our strategic plan, which includes: the potential need for capital, partnerships, venture debt opportunities and business development opportunities. We have significantly reduced our monthly expenditures to extend our cash runway while finalizing our efforts. At this time we have received several non-binding term sheets for a potential partnership agreement within the pharmaceutical industry. The Company is still in negotiations, has not executed a definitive agreement, and no party is under any obligation to enter into or continue negotiations regarding a definitive agreement related to any transaction.
Leadership
In May of this year, we announced the appointment of Keith Dewedoff to the position of Interim Chief Financial Officer (CFO). Mr. Dewedoff’s depth of expertise in finance within biotech, and his experience in executing growth capital initiatives, as well as corporate development and equity research, brought crucial talents into the Company at the right time. Mr. Dewedoff’s contributions have been significant.
Following Mr. Dewedoff’s appointment and after an exhaustive international search, in June we engaged Elena Thyen-Pighin, an experienced finance executive, to transition into the role of permanent CFO & Head of Finance / Human Resources. Ms. Thyen-Pighin’s position will be effective on September 1, 2023. Ms. Thyen-Pighin holds extensive experience in leadership and management functions as both head of finance and human resources across a number of industries, including organizations similar to NLS. Based in Switzerland, Ms. Thyen-Pighin speaks 5 languages and has a strong and successful track record, most notably in accounting for both private and publicly listed enterprises. Her responsibilities will include oversight of all financial operations as well as those related to human resources. We are thrilled to welcome her to the leadership team.
Mazindol ER
In July of 2023, NLS announced that the Phase 3 clinical trial (which we call the AMAZE Program) protocol to evaluate the safety and efficacy of Mazindol ER in patients with narcolepsy type 1 received approval from the independent Institutional Review Board (“IRB”). The AMAZE Program encompasses two almost-identical double-blind Phase 3 studies (N=50 each) investigating Mazindol ER versus placebo in adult patients with narcolepsy commencing this summer at multiple sites exclusively in the U.S. Based on the U.S. Food and Drug Administration’s (FDA) recommendations, both Phase 3 trials will measure the weekly cataplexy episodes as the primary endpoint over 8 weeks of treatment and excessive daytime sleepiness as a secondary objective using the Patient-Reported Outcomes Measurement Information System (PROMIS-SRI) and the Epworth Sleepiness Scale (ESS).
Along with IRB approval and the green light from the FDA, NLS has retained a contract research organization (CRO) and has enrolled a number of sites for the phase 3 studies. Once suitable capital has been secured, the phase 3 program will immediately commence as the sites are ready to begin enrolling patients.
On August 25, 2023, NLS submitted a fast-track designation application for Mazindol ER for the treatment of narcolepsy to the FDA. Fast track is a designation by the FDA of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need. A drug may be granted Fast Track Designation if it is believed to have an impact on patient survival, day-to-day functioning, or if it is believed that the condition will progress in severity if left untreated. Standard reviews by the FDA for drug approval generally take about one year. A medicine that receives Fast Track Designation can be on the market within six months of the regulatory application.
Medical Congress Activities
At SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), NLS presented our findings highlighting data from the recently completed Phase 2 multi-center U.S. clinical study evaluating Mazindol ER, a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, in adult patients suffering from narcolepsy, which study met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. We believe that these results confirm the efficacy of Mazindol ER, as well as the safety and tolerability profile established in over 40 years of on-label and off-label use. Additional data from our Open Label Extension study (NLS-1022) further validated the positive results from our Phase 2 double-blind trial for Mazindol ER in narcolepsy and demonstrated the potential long-term efficacy, tolerability, and safety of the treatment.
In addition to presenting our findings, we spoke to hundreds of clinicians at our booth as well as presented to a packed room in our symposium entitled, Mazindol ER: Pioneering the Combination of SNDRI and OX2R in the Treatment of Narcolepsy, in which we, along with internationally renowned key opinion leaders (KOLs) in sleep medicine, Bruce Corser, M.D., Medical Director, Sleep Management Institute, Cincinnati, and Clete Kushida, MD, PhD, Chief and Medical Director, Division of Sleep Medicine, Stanford School of Medicine, presented on:
Unmet needs in the treatment of Narcolepsy
Phase 2 Clinical Data presentation for Mazindol ER (Studies NLS-1021 & NLS-1022)
Phase 3 Program Summary for Mazindol ER (Studies NLS-1031, NLS-1032 & NLS-1033)
NLS’ Pipeline
Progressing our Pipeline
The NLS current pipeline bridges the present to the future, providing a holistic approach and further strengthening the Company’s vision to awaken a brighter future for patients by overcoming rare and complex CNS diseases. We believe that our pipeline products are well positioned as we gain ground in establishing future market positions through patents for lauflumide (NLS-4) and other new chemical entities and assets. With extensive intellectual property (IP) coverage in the U.S., Japan and Europe, and promising pre-clinical data, we anticipate that our wake-promoting agent, lauflumide (NLS-4), could also offer a new option for the treatment of chronic fatigue, including fatigue associated with cancer treatment and long-COVID symptoms. We anticipate that clinical trials with lauflumide (NLS-4) will begin in 2024.
As we strive to develop better therapies to safeguard and empower the brain throughout all stages of life, these compounds, including Mazindol ER for the treatment of narcolepsy, along with NLS-4 focused on idiopathic hypersomnia and chronic fatigue, and NLS-11, addressing Kleine-Levin Syndrome and neurodegenerative diseases (e.g. Lewy body dementia), would offer much-needed treatment options to fill the gaps for patients with these disorders.
Current NLS pipeline products focused on Sleep disorders:
In May of this year, NLS presented new and compelling preclinical data on four of our pipeline compounds at the annual meeting of the American Society of Clinical Psychopharmacology (ASCP), in Miami, Florida. NLS’ Chief Scientific Officer, Eric Konofal, MD, PhD, presented data highlighting the Company’s focus on and investment in therapeutic areas of rare hypersomnia disorders and complex neurologic disorders:
Effects of NLS-4 (Lauflumide) and modafinil in a rat model of chronic severe fatigue
Effects of NLS-8 (Melafenoxate) on memory in a model of Alzheimer’s Disease, the scopolamine-induced amnesia in the novel object recognition test in mice
Effects of NLS-11 (Benedin) on memory in the novel object recognition test in mice
Effects of NLS-12 (Oxafuramine) on memory in the novel object recognition test in mice
We will continue to explore opportunities and execute on possibilities based on key factors such as unmet medical needs, biological rationales, safety profiles, feasibility of clinical development, potential for leveraging accelerated development pathways for regulatory approval, strong IP positions, favorable competitive landscapes, and attractive commercial potential.
The NLS discovery platform continues to focus on single molecules that function through multiple mechanisms designed to target the complexity of the CNS disease state. Our goal remains building a differentiated global pharmaceutical company that is patient-centered and dedicated to the development of transformative therapies addressing critical unmet needs. As we navigate the competitive landscape of our industry while focusing on the development of our product candidates, we are poised to maximize the therapeutic potential of our current pipeline while still pursuing new candidates that will continue to broaden our product portfolio.
Unwavering Support
At our Annual General Meeting (AGM) in July, NLS shareholders approved all of the Board of Directors’ proposals for the AGM that took place in Zürich, Switzerland on June 30, 2023. This included the election of Audrey Greenberg and Dr. Anthony Walsh to the Board of Directors, shareholder approval of financial statements, the compensation report and the balance sheet results of the Company for the fiscal year 2022. Shareholders also approved the total compensation budgets for NLS’ Board of Directors and Executive Management for the financial year 2024. PricewaterhouseCoopers AG was re-elected as NLS’ independent auditors for another term. Other key highlights from the meeting include 64% percent of the shares entitled to votes being represented and the Board of Directors receiving the highest voting approval in the Company’s history with 99.5% of votes cast in favor of the proposals.
A Bright Future
More than ever, we at NLS are committed and passionate to be a part of a company with genuine near and long-term prospects to change the lives of patients with rare CNS diseases. We work together in order to create a culture that inspires and motivates our team members to do what they do best. Our leadership team remains nimble with an honest approach to transparent communication, empowerment and individual ownership of responsibilities. Our team members thrive in finding innovative and efficient approaches to advance our corporate aspirations.
Together with our co-founder, Dr. Eric Konofal, I want to offer my sincerest gratitude to the clinical investigators and participating patients making it possible for Mazindol ER to be a potential class-leading treatment for narcolepsy in the future. I must also thank the many women and men across Europe and the U.S. that are part of the NLS team, from pre-clinical to regulatory affairs to supply chain and all in between, that endeavor every day to progress our objectives in treating these rare diseases. And finally, I would like to thank you, our shareholders and investors, for your continued support for and shared commitment to NLS.
With gratitude,
Alex Zwyer Chief Executive Officer
COMPANY HIGHLIGHTS
Mazindol ER has successfully completed a Phase 2 trial, including OLE, for narcolepsy treatment: projected to be $4.5B annual market by 2027**
Orphan Drug Designation (ODD) granted in the US and Europe
AMAZE phase 3 program starting in July 2023, secured funding for current projects and existing operations through 2025. Development of Mazindol ER is in the spotlight for progression purposes, particularly for the treatment of EDS and cataplexy in adult patients who suffer from narcolepsy
Named Patient Program for patients suffering from idiopathic hypersomnia launched in target markets across Europe
Key Executive Leadership roles filled
Pipeline progressed and expanded with long-dated IP protections in major markets
Over 100 patents in over 140 countries including technology and application for a variety of diseases such as ADHD, Cancer Fatigue, Parkinson’s and more. Not to mention that several products are nearing the end of Phase 2 and approaching NDA filing
POLARIS: Mazindol ER Phase 2 Program in Narcolepsy, consisted of two US clinicaltrials approved by the FDA, met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. These results were promising, i.e, Sustained EDS and cataplexy improvements at all time points. OLE conclusions: 6-month OLD, displayed good subject participation (87%) and retention (11.5%)
Partnership with Université de Lausanne (UNIL) (preclinical projects), University of Berne (narcolepsy reserach), Swiss Narcoslpsy Network (narcolepsy reserach) ( (BVF Partners L.P (financial partnership)
Partnerships with Patient advocacy groups including Narcolepsy Network, The Narcolepsy Foundation, The Sleep Consortium, Hypersomnia Foundation, and Wake Up Narcolepsy
PIPELINE
NLS PHARMACEUTICS TO PROCEED WITH PHASE 3 CLINICAL PROGRAM (AMAZE) FOR MAZINDOL ER FOR THE TREATMENT OF NARCOLEPSY FOLLOWING FDA REVIEW AND IRB APPROVAL OF THE FULL STUDY PROTOCOL
ZÜRICH, SWITZERLAND / ACCESSWIRE / July 3, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the full protocol for the NLS-1031 study, part of the Phase 3 program for Mazindol ER, called AMAZE. In addition, the Company is pleased to announce that the Phase 3 clinical trial protocol to evaluate the safety and efficacy of Mazindol ER in patients with narcolepsy type 1 received approval from the independent Institutional Review Board (“IRB”). The AMAZE Program will encompass two almost-identical double-blind Phase 3 studies (N=50 each) investigating Mazindol ER versus placebo in adult patients with narcolepsy commencing this summer at multiple sites exclusively in the U.S.
Based on the FDA’s recommendations, both Phase 3 trials will measure the weekly cataplexy episodes as the primary endpoint over 8 weeks of treatment and excessive daytime sleepiness as a secondary objective using the Patient-Reported Outcomes Measurement Information System (PROMIS-SRI) and the Epworth Sleepiness Scale (ESS).
“In addition to IRB approval of the Phase 3 study protocol for AMAZE obtained last week, with this regulatory milestone acheived, we can recruit U.S. clinical sites quickly and efficiently, allowing us to move forward with providing Mazindol ER to patients with narcolepsy type 1,” commented George Apostal, MD, MS, Chief Medical Officer of NLS.
Patients who complete these studies will be offered participation in a 12-month open-label extension (OLE) study To be eligible for enrollment into the OLE study, patients must be at least 18 years of age and have been diagnosed with narcolepsy with cataplexy.
Alex Zwyer, Chief Executive Officer of NLS, said, “We are pleased with the FDA’s review of the Phase 3 protocol and now expect to move quickly to begin enrolling patients in the AMAZE program in centers across the U.S. in the coming days.”
NLS previously reported on the Phase 2 study results in narcolepsy in which Mazindol ER met all primary and secondary endpoints. Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the OLE study and patients treated with placebo in the randomized Phase 2 trial and who subsequently received Mazindol ER in the OLE study showed similar efficacy with the Mazindol ER-treated patients in the randomized trial. Data from the Phase 2 studies were presented in early June at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS). A recording of the Phase 2 data presentation can be found here: https://nlspharma.com/news/nls-satellite-symposium/.
An IRB operates under FDA regulations and is an FDA registered constituted group that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with FDA regulations, an IRB has the authority to approve, require modifications (to secure approval), or disapprove research. The purpose of IRB review is to assure, both in advance and by periodic review, that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in the research. To accomplish this purpose, IRBs use a group process to review research protocols and related materials (e.g., informed consent documents and investigator brochures) to ensure the protection of the rights and welfare of human subjects of research.
LEAD ASSET: MAZINDOL ER
Mazindol ER is a patented and proprietary formulation of the active compound mazindol, and are designed for once-daily dosing. Mazindol has a well-established safety record from its long history of clinical use in the United States and in Europe when the drug was approved in an immediate release formulation for the management of obesity. Mazindol was marketed for nearly 30 years under the trade name Sanorex® before being voluntarily withdrawn from the market, and the drug is no longer available nor marketed in these regions. During its time on the market, mazindol was also widely used off-label and prescribed under compassionate use for the treatment of narcolepsy for several decades. Use in these compassionate use programs has yielded evidence of positive efficacy in patents suffering from the symptoms of narcolepsy including patients that were refractory to approved treatments for the disorder. Additionally, these same programs, a retrospective analysis of investigator sponsored studies, and NLS’s own trial evaluating Mazindol ER in patients with ADHD provide evidence of the drug’s favorable safety profile at doses that yielded efficacy signals.
We believe that our lead product candidate, Mazindol ER, offers a differentiated profile with clincally meaningful advantages over current treatment options for narcolepsy for the following reasons:
MECHANISM OF ACTION
If approved, Mazindol ER would be the only partial orexin 2 receptor agonist as well as the only triple monoamine reuptake inhibitor approved by the FDA for the treatment of narcolepsy. Narcolepsy is caused by a profound loss of orexin producing neurons. A partial orexin 2 receptor agonist may help to replace missing endogenous orexin peptide, addressing the underlying cause of the disease. In addition, the drug’s action as a triple monoamine reuptake inhibitor can further reduce disease specific symptoms, offering patients a treatment option that may address the two primary symptoms of narcolepsy – excessive daytime sleepiness (EDS) and cataplexy attacks – in a convenient once-daily oral tablet.
LOW POTENTIAL FOR ABUSE, MISUSE, AND DIVERSION.
Mazindol is currently classified by the DEA as a Schedule IV controlled substance . The DEA defines Schedule IV controlled substances as those “with a low potential for abuse and a low risk of dependence”. Unlike Xyrem® (sodium oxybate), the top-selling treatment for narcolepsy in the United States deemed to have a high potential for abuse/misuse (Schedule III), mazindol was never required by the FDA to have a risk evaluation and mitigation strategy (REMS) program in place to manage known or potential serious risks associated with its use.
QUILIENCE® HAS POTENTIAL TO BE ADMINISTERED AS A MONOTHERAPY.
Narcolepsy is a difficult disorder to manage and even with available treatments, the majority of narcolepsy patients often require multiple medications to treat their symptoms. According to the current treatment guidelines (initially published in 2007) of the American Academy of Sleep Medicine, or AASM, medications for narcolepsy, at best, provide only moderate improvement in narcolepsy symptoms, and their respective side effects may limit their use. The AASM specifically highlights that future investigations should be directed toward more effective and better tolerated therapies for treatment. The Voice of the Patient report from the FDA’s patient-focused drug development initiative, published in 2014, concluded that, based on the overall benefit-risk assessment of current medications, there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy. A retrospective analysis (Nittur et.al, Sleep Med. 2013 Jan;14(1):30-6) showed that mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant patients with hypersomnia, including a clear benefit on the two primary symptoms of narcolepsy–EDS and cataplexy.
MAZINDOL ER IS BEING DEVELOPED AS A ONCE-DAILY ORAL TABLET ADMINISTERED IN THE MORNING UPON WAKENING.
Patients have identified a need for treatment options that are easier to take, dosed less frequently, do not disrupt nighttime sleeping, and provide full day coverage of symptoms. We believe that once-daily dosing with Mazindol ER may address this need and may help improve patient compliance and adherence with treatment. Mazindol ER utilizes our patented and proprietary extended-release (ER) formulation and is being designed to optimize its pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long-acting symptom control to uniquely meet the needs of patients.
RELATIONSHIP BETWEEN NARCOLEPSY AND ADHD
Narcolepsy and psychiatric disorders have a significant but under-recognized relationship in which the two may coexist. However, narcolepsy is frequently misdiagnosed initially as a psychiatric condition, contributing to protracted times for accurate diagnosis and treatment. Narcolepsy is a disabling neurological condition that carries a high risk for the development of social and occupational dysfunction. Deterioration in function associated with narcolepsy may lead to the secondary development of psychiatric symptoms and inversely, the development of psychiatric symptoms can lead to a deterioration in function and quality of life. The overlap in treatments may further enhance the difficulty to distinguish between diagnoses.
ADHD is the most common neurobehavioral disorder characterized by symptoms of inattention, impulsivity and hyperactivity with an estimated prevalence rate of approximately 4-12% worldwide, as reported by the paper, “Understanding Attention Deficit/Hyperactivity Disorder From Childhood to Adulthood,” by Drs. Timothy E. Wilens and Thomas J. Spencer.
On the surface, ADHD may appear to be the opposite of narcolepsy; however, there may actually be significant clinical similarities between the two disorders. Cumulative data on sleep problems in children and adolescents with ADHD have shown that children with ADHD have had a higher rate of restless sleep, impaired sleep, and daytime sleepiness than children without ADHD. However, it is unclear whether EDS in ADHD is due to nocturnal sleep disturbances or primary vigilance disorders because shorter sleep onset latency is assessed in ADHD patients by the Multiple Sleep Latency Test, rather than in the control group irrespective of the presence/absence of sleep disturbances.
Alternatively, problems with sleep may represent an intrinsic component of ADHD. The presence of ADHD symptoms in children and adolescents with narcolepsy has been found to be about two-fold higher than in the general control population. Adults with narcolepsy have been found to have a much greater likelihood of having a diagnosis of ADHD in childhood compared to the general control population. Hyperactivity seen in ADHD may, in fact, be a compensatory response for individuals who are under-aroused or sleepy, and ADHD symptoms contribute to poor quality of life and increased frequency of depressive symptoms, similar to narcolepsy. To the best of our knowledge, almost all of the treatments used in ADHD have mechanistic overlap with treatments used in narcolepsy for EDS, and researchers suggest that the symptoms of EDS, fatigue, and sleep fragmentation may be the cause for ADHD symptoms, which is consistent with similar findings in other hypersomnia disorders.
NLS PHARMACEUTICS RECEIVES GREEN LIGHT FROM THE U.S. FDA TO PROCEED WITH PHASE 3 CLINICAL PROGRAM (AMAZE) FOR QUILIENCE(R) (MAZINDOL ER) FOR THE TREATMENT OF NARCOLEPSY
ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed with the Phase 3 program for Quilience® (Mazindol ER). The AMAZE Program will encompass two double-blind Phase 3 trials (N=50 each) investigating Mazindol ER versus placebo in adult patients with narcolepsy, commencing this summer at multiple sites in the U.S.
Both phase 3 trials, NLS-1031 and NLS-1032, will measure the weekly cataplexy episodes as the primary endpoint over 8 weeks of treatment. Patients who complete these studies will be offered participation in a 12-month open-label extension (OLE) study (Study NLS-1033). To be eligible for enrollment into the program, patients must be at least 18 years of age and have been diagnosed with narcolepsy with cataplexy.
Alex Zwyer, Chief Executive Officer of NLS, said, “We thank the FDA for the approval of this clinical program to evaluate Quilience® in chronically ill patients suffering from narcolepsy and we are thrilled to start recruiting for the U.S. clinical trial this summer. Today’s announcement builds on our commitment and focus to awaken a brighter future for patients with rare and complex central nervous system diseases.”
NLS previously reported on the Phase 2 study results in narcolepsy in which Quilience (Mazindol ER) met all primary and secondary endpoints. Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the OLE study and patients treated with placebo in the randomized Phase 2 trial and who subsequently received Mazindol ER in the OLE study achieved comparable results to the Mazindol ER-treated patients in the Phase 2 trial. Data from the Phase 2 studies will be presented at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), which is being held from June 3 – 7, 2023, in Indianapolis.
“We are pleased that the FDA has approved our clinical development plan in narcolepsy patients. We believe that the FDA’s approval affirms the Company’s path to securing approval for Mazindol ER in order to treat a life-long chronic disorder with high unmet medical needs,” says George Apostol, Chief Medical Officer.
Co-founder of the company, serial entrepreneur, served as COO at Viforpharma AG (global pharmaceutical company with a revenue of 1.99B in 2021) and a director since the company’s incorporation in 2015, been there since the beginning. Over 25 years of International business experience, notably when he served under Vifor International, global regulatory affairs, sales and marketing, furthermore was involved in the forefront of business development where he lead over 100 BD deals
Eric Konofal M.D. (CSO and Co-Founder):
Drug hunter and co-founder of NLS pharmaceutics, main expertise lies in his knowledge for clinical and scientific research. He’s a senior medical consultant for the Pediatric Sleep Disorders Center as well as the Principal Clinical Investigator at the Clinical Pharmacology and Pharmacogenetic Department at Robert-Debre University of Paris. Dr. Konofal has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases, in fact it was Dr. Konofal that obtained the U.S. patent for mazindol (used in the treatment of ADHD), one of the key ingredients to the growth and development for the NLS pipeline (Mazindol ER Clinical Development Program.
George Apostol M.D. (CMO, Global Head R&D)
Worked in large pharma R&D organizations for more than 20 years. Broad drug development expertise across early,middle and late phases of development at the Global R&D organizations of Eli Lilly,Pfizer, Abbott, Novartis, Shire and Endo. Received distinguished R&D awards and achieved multiple regulatory approvals inUS, EU and Japan.
Keith Dewedoff (CFO)
More than 20 years of experience in the life science industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Extensive expertise in strategic financial management, serving as CFO in organizations including Danforth Advisors, Code Bio, Ceptur Therapeutics and more than 10 other privately held and public companies at various life cycle stages.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY NLSP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We have another brand new profile that we have never featured on this newsletter before.
This is a company that has been on the move over the last 4 sessions, moving from 1.27 to highs of 2.56 today on massive interest.
Pull up BNOX immediately.
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need.
Bionomics also is developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need.
Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain.
The α7 nicotinic acetylcholine (“ACh”) receptor (“α7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance.
Utilizing their expertise in ion channel biology and translational medicine, they are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the α7 receptor to treat anxiety and stressor-related disorders and cognitive dysfunction, respectively.
BNOX‘s expertise and approach have been validated through their June 2014 research collaboration and license agreement with Merck & Co. for their α7 receptor PAM program, which targets a receptor that has garnered significant attention for treating cognitive deficits.
This partnership enables them to maximize the value of their ion channel and develop transformative medicines for patients suffering from cognitive disorders such as Alzheimer’s disease.
BNC210
Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective NAM of the α7 receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). There remains a significant unmet medical need for the over 22 million patients in the United States alone suffering from SAD and PTSD.
BNC210 Holds the Potential to Addresses the Shortcomings of Existing Therapies
There is a significant need for improved therapeutics for SAD and PTSD with improved efficacy and response rates, fewer side effects and a faster onset of action, which we believe may be achieved by targeting a different mechanism of action.
BIONOMICS COMPLETES LAST PATIENT LAST VISIT IN THE PHASE 2B ATTUNE STUDY FOR POST-TRAUMATIC STRESS DISORDER (PTSD) AND CONFIRMS EXPECTED 2023 MILESTONES WITH ITS LEAD ASSET BNC210
The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSD
Topline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected by the end of September 2023
An end-of-phase 2 (EoPh2) meeting with the U.S. Food and Drug Administration (FDA) has been scheduled for September 2023 to review results from the Phase 2 PREVAIL study in patients with Social Anxiety Disorder (SAD) and to obtain feedback on a proposed Phase 3 registrational program
Bionomics is scheduled to delist from the Australian Securities Exchange on 28 August 2023
ADELAIDE, Australia, and CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD.
“We continue our strong momentum with our fast track designated BNC210, with a robust clinical and regulatory milestone-rich year in both SAD and PTSD, two highly prevalent neuropsychiatric disorders with significant unmet needs,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study. We also look forward to our EoPh2 meeting with the FDA next month, where we will discuss our promising results from the PREVAIL study in SAD and the proposed Phase 3 clinical program.”
The Phase 2b ATTUNE study (NCT04951076) is a double-blind, placebo-controlled, randomized study of twice daily BNC210 as monotherapy treatment for PTSD. The primary endpoint is change in a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to week 12 compared to placebo. Secondary endpoints include change from baseline to week 12 compared to placebo on the PTSD-checklist (PCL-5), anxiety (Hamilton Anxiety Rating Scale, HAM-A), depression (Montgomery-Asberg Depression Rating Scale, MADRS), Clinician Global Impression (CGI), Patient Global Impression (PGI), sleep (Insomnia Severity Index, ISI) and disability (Sheehan Disability Scale, SDS) scales. Approximately 200 participants have been enrolled at 27 sites in the United States and 7 sites in the United Kingdom, and topline results are anticipated by the end of September 2023.
The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023. At this meeting, Bionomics will discuss with the FDA its plans for a Phase 3 program that would support the submission of a new drug application for BNC210 for the treatment of SAD. The Company believes that the results from Phase 2 PREVAIL study support the progression of BNC210 into Phase 3 and plans to provide an update by the end of 2023 following the receipt of formal meeting minutes from the FDA.
Additionally, Bionomics is scheduled to delist from the Official List of the Australian Securities Exchange on 28 August 2023. The Company will remain an Australian incorporated company and will maintain its listing of ADSs on Nasdaq under the trading symbol ‘BNOX’.
______________________
Near Term Clinical and Regulatory Milestones Anticipated
Q3’23: Topline data from placebo-controlled Phase 2b ATTUNE study of BNC210 in PTSD
2H’23: FDA End of Phase 2 meeting to discuss registrational program for BNC210 in Social Anxiety Disorder
Q4’23 / Q1’24: Potential for first patient dosed in Phase 3 study of BNC210 in Social Anxiety DisorderPartnerships and Collaborations Support Early-Stage Programs
Merck partnership for Phase 1 candidates targeting cognitive deficits in Alzheimer’s and other CNS disorders
Memorandum of understanding with EmpathBio for feasibility assessment of EMP-01 (MDMA derivative) & BNC210 for PTSD treatment
Other partnering opportunities include preclinical assets targeting potassium (Kv) and sodium (Nav) ion channels
Bionomics Highlights
Targeting Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and cognitive dysfunction associated with Alzheimer’s disease, schizophrenia and other CNS conditions
Large underserved markets with over 25 million patients in the US alone suffering from SAD and PTSD and no new FDA approved therapies in nearly two decades
BNC210 (negative allosteric modulator of the α7 nicotinic acetylcholine receptor)
Clinical proof of concept in Generalized Anxiety Disorder (GAD2) and panic attack model
In Phase 2 PREVAIL trial with FDA Fast Track designation for acute treatment of SAD
In Phase 2b ATTUNE trial with FDA Fast Track designation for treatment of PTSD
Partnerships & Collaborations
Strategic partnership with Merck for treatment of cognitive deficits in Alzheimer’s and other CNS disorders
EXISTING PARTNERSHIPS
MERCK Α7 RECEPTOR PAM COLLABORATION
In June 2014 Bionomics entered into in 2014 to develop α7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions
Merck funds all R&D activities including clinical development and worldwide commercialization of any products from collaboration
Payments received: US$20M upfront and US$10M for Phase 1 milestone
Eligible to receive up to US$465M in additional milestone payments plus royalties
In 2021 Bionomics entered into a Memorandum of Understanding with EmpathBio, which sets out an initial collaborative framework of preclinical studies to collectively explore a combination drug treatment regimen with BNC210 and EMP-01 (3,4 Methylenedioxymethamphetamine (MDMA) derivative).MDMA-assisted psychotherapy has demonstrated significant symptom improvement in PTSD patients and FDA has granted a Breakthrough Therapy designation to MDMA-assisted psychotherapy. Empath Bio is developing MDMA derivatives that may permit the entactogenic effects of MDMA to be separated from some of the known adverse effects.
EXCLUSIVE BNC101 ONCOLOGY LICENSE AGREEMENT FOR THE DEVELOPMENT OF CAR-T THERAPEUTICS
In 2020 Bionomics announced that it has entered into an exclusive Agreement to license Bionomics’ BNC101 oncology drug candidate to Carina Biotech (Carina), for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body’s immune system to fight cancer.
Under the worldwide, exclusive License Agreement, Carina will fund all research and development activities. Bionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development.
In September 2021, Carina announced that it plans to initiate a clinical trial of BNC101 CAR-T therapy for the treatment of advanced colorectal (bowel) cancer in late 2022.
SPYRIDON “SPYROS” PAPAPETROPOULOS, M.D., PHD PRESIDENT & CHIEF EXECUTIVE OFFICER
Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders. He held various positions of increasing responsibility at CNS-focused start-up/small, medium specialty and large biopharma companies. Prior to joining Bionomics Ltd. he served as Chief Medical Officer of Vigil Neuroscience Inc, (NASDAQ: VIGL), as Chief Development Officer, and SVP, Head of Clinical Development at Acadia Pharmaceuticals Inc (NASDAQ: ACAD)., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion Inc. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Spyros has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (20+ INDs and multiple NDAs/BLAs) and new product approvals and launches worldwide.
MR ADRIAN HINTON BEC, FCA
FINANCIAL CONTROLLER
Mr Hinton has had a long career with Deloitte (Adelaide) of over 43 years, retiring 1 July 2018 as Principle in the Audit and Assurance Group. He was responsible for managing the audit services to various Adelaide based public and private companies. His experience has given Mr Hinton a broad-based knowledge of contemporary accounting and audit issues inclusive of experience in working with a wide range of clients in different industries, from listed entities, private corporations to major subsidiaries of multinational listed companies, covering consumer, agriculture, retail, manufacturing, automotive, biopharmaceutical and resources sectors. Mr Hinton also has experience in preparing due diligence reviews, investigative accounting reports and the review of profit forecasts. Mr Hinton’s experience is currently benefited by being on the Boards of The Multiple Sclerosis Society of South Australia and Northern Territory, Carers Association of SA Inc, Australia PNG Alliance Group Pty Ltd and the Audit and Risk Committee of the University of South Australia. Mr Hinton also volunteers his time and skill set to aiding community groups both locally and internationally.
Ms Liz Doolin MSc
VICE PRESIDENT CLINICAL DEVELOPMENT
Ms Doolin has over 25 years international experience in drug discovery, clinical and life sciences research. She joined Bionomics Limited in 2008 to lead the early clinical development program for BNC210, a small molecule with therapeutic potential for anxiety disorders, and trauma and stressor-related disorders including PTSD. Ms Doolin currently leads Bionomics’ clinical programs across central nervous system disorders and oncology, including three novel investigational drugs in Phase 1 and 2 clinical development. In addition to her extensive clinical research experience in Australia, Ms Doolin has a strong immunology and biotechnology research background, as well as biopharmaceutical development and GMP manufacturing experience, gained in New Zealand and the UK.
Julie Kerner PhD SVP Business Operations
Julie is a biotech leader and enterprise thinker with 15+ years of drug development from early research through commercialization. Under her leadership, companies created portfolio and platform strategies, filed 10+ IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Most recently, Julie worked at Fulcrum Therapeutics and Aliada Therapeutics driving pipeline strategy and program leadership. Prior to that, she worked at AVROBIO, Wave Life Sciences, and Biogen working across R&D, Marketing, and early product planning. Before she joined industry, Julie earned a PhD in Neuroscience at Tufts Medical School and was a market analyst at Decision Resources, writing over 10 reports on neurodegeneration, psychology, and pain. Julie is committed to patient centricity and advocacy, sitting on the boards of Newton Wellesley Hospital, National Braille Press, and the US Neuroacanthocytosis advocacy, Inc.
DR. ATUL R. MAHABLESHWARKAR MD ACTING CMO
Dr. Mahableshwarkar is a seasoned Pharma Executive with strategic, developmental and regulatory experience in large global and small startup companies who has submitted INDs and NDAs leading to drug approvals. He is a Board Certified Psychiatrist, who graduated from the Armed Forces Medical College in India and completed a residency in Psychiatry and a fellowship in Neuropsychiatry from The Rosalind Franklin University of Health Sciences/The Chicago Medical School where he was an Associate Professor and Vice Chair of the Department of Psychiatry and Behavioral Sciences and also the Leader of the Mental Health Services Product Line at the North Chicago VAMC where he managed the mental health care to veterans at a hospital with over 800 inpatient beds. He’s had leadership roles as CMO and SVP/VP/Senior Director at small and large companies including Emalex Biosciences, BlackThorn Therapeutics, and Takeda. Dr. Mahableshwarkar has over 180 scientific publications, posters, and oral presentations with a track record of guiding programs to successful outcomes.
MR. TIM CUNNINGHAM MBA
CHIEF FINANCIAL OFFICER
Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company’s growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY AMPLIFYIR LLC FOR A ONE DAY BNOX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We have another exciting opportunity that we want you to research immediately for tomorrow’s session.
Pull up ALBT immediately.
This is one saw a major bounce on Friday, closing up 10% on light interest.
LET’S TAKE A LOOK AT THE MAJOR CATALYSTS FOR THIS ONE:
Image Source (2)
The global clinical laboratory service market is poised for significant expansion, with an estimated value of $202 billion and projected growth surpassing $315 billion by 2030. This market is primarily driven by the increasing demand for early diagnostic tests and the rising prevalence of chronic diseases. The biotechnology and healthcare industries, particularly in developed regions like the U.S. and Canada, are experiencing rapid growth, further fueling the demand for clinical laboratory services. Government and private investments aimed at developing and expanding these industries are key drivers of market growth. (2)
The rising prevalence of chronic diseases and increased investments in research laboratories have a significant impact on the demand for clinical laboratory services. Additionally, the need for efficient data storage and management, driven by the proliferation of research centers worldwide, contributes to market growth. The adoption of automated technologies to enhance productivity and reduce costs also augments the market’s expansion. Key players in the industry continually introduce new services to meet patient needs, further propelling market growth.
The clinical chemistry segment, which accounted for a significant revenue share, is projected to maintain its dominance throughout the forecast period. This segment benefits from the introduction of new technologies, a wide range of clinical chemistry tests, and the emergence of point-of-care testing methods. Moreover, investments in research activities by healthcare industry players drive the growth of laboratories globally, making the clinical chemistry segment the fastest-growing segment. (2)
The human and tumor genetics tests segment is expected to register the highest growth rate, indicating the increasing importance of genetic testing in diagnosis and treatment.
Among service providers, hospital-based laboratories currently hold the largest revenue share. Factors such as the growing prevalence of cancer, research activities aimed at innovative services, and the rising demand for clinical chemistry services in hospitals contribute to the growth of this segment.
The toxicology testing services segment is anticipated to exhibit the fastest growth rate. Advancements in clinical diagnostic methods and increasing awareness about disease diagnosis and treatment contribute to the growth of this segment.
The global clinical laboratory service market offers promising growth prospects, driven by the increasing demand for early diagnostic tests and the rising prevalence of chronic diseases. Investments in research laboratories, automation technologies, and the introduction of new services by key players further contribute to market expansion. (2)
As the market evolves, opportunities for growth and innovation abound. One little-known company to keep an eye on in this sector is Avalon GloboCare Corp. (Nasdaq: ALBT). This company could be extremely well-positioned to capitalize on these opportunities and make significant contributions to the advancement of the industry. (8)
AVALON GLOBOCARE CORP. (NASDAQ: ALBT) GAINS A FOOTHOLD IN A $315B DIAGNOSTICS MARKET…(2)(6)
Image Source(12)
Avalon GloboCare Corp. (NASDAQ: ALBT) recently announced its acquisition of a 40% interest in Laboratory Services MSO, LLC (LSM), a premier clinical diagnostics and reference laboratory. The transaction marks the launch of Avalon’s new rollup strategy targeting toxicology and pharmacogenetic laboratories. (6)
Headquartered in Costa Mesa, California, LSM provides a wide range of diagnostic tests, including drug testing, toxicology, pharmacogenetics, and various test services, from general blood work to anatomic pathology. The laboratory also has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory.
The total consideration for the transaction was $21 million, with $9 million paid in cash, $11 million in shares of the Company’s Series B preferred stock, and $1 million in cash payable on February 9, 2024. The seller is also eligible to receive certain earnout payments upon achieving specific operating results, which could amount to $10,000,000. (6)
The parties entered into an operating agreement in connection with the transaction, which includes a pro-rata percentage of LSM’s net income. Additionally, Avalon has an exclusive option to purchase an additional 20% of LSM for $6 million in cash and $4 million in additional shares of the Company’s Series B preferred stock.
David Jin, M.D., Ph.D President and Chief Executive Officer of Avalon, stated that this transaction is expected to be accretive to earnings and will add strong clinical and rollup synergies to the existing Avalon portfolio and future growth plan. Dr. Jin also expressed excitement about the potential to acquire a controlling interest in LSM within the next nine months.
Avalon aims to leverage LSM’s experience and infrastructure to achieve significant synergies with respect to revenue growth and market shares by targeting laboratories with exceptional performance, positive revenue track records, and niche-market advantage.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, “We are excited to close this initial investment as a first step, and anticipate acquiring a controlling interest within the next nine months. Not only is this transaction expected to be accretive to our earnings, but we believe it also adds strong clinical and rollup synergies to the existing Avalon portfolio and future growth plan. By combining LSM’s established infrastructure with Avalon’s cutting-edge diagnostic and cellular immunotherapy platforms, it provides us with an established roadmap and framework in the context of integrating our CellTech/therapeutic programs with precision medicine.”
Image Source (23)
In a significant move that underscores its commitment to expansion and innovation, Avalon GloboCare Corp. (Nasdaq: ALBT) has announced the acquisition of DE Laboratory LLC, a reputable laboratory located in Houston, Texas. This strategic acquisition, executed by Avalon’s Laboratory Services MSO, LLC, presents a multitude of growth opportunities and solidifies Avalon’s presence within the dynamic landscape of laboratory testing and services. (22)
DE Labs has made its mark as a CLIA-certified and COLA-accredited laboratory, providing a comprehensive array of high-quality testing services. With a specialization in various crucial fields, including drug testing, genetic testing, urinary testing, and CV-19 PCR testing, DE Labs has emerged as a reliable destination for accurate diagnostics and analyses. Handling an impressive volume of 1,500 lab tests each month, the laboratory’s reputation for precision and efficiency has garnered the trust of both healthcare professionals and patients alike.
Avalon’s acquisition of DE Labs is not just a strategic decision, it’s a calculated move aimed at harnessing the vast potential for growth within the laboratory testing sector. The laboratory is now being operated as a wholly-owned subsidiary of LSM, with Avalon owning a substantial 40% interest in LSM. This ownership structure positions Avalon to leverage DE Labs’ expertise while contributing its own resources and insights to foster a symbiotic relationship.
One of the most compelling aspects of this acquisition is the planned expansion of DE Labs’ reach into the surrounding counties. With Avalon’s support, LSM is directing growth capital towards geographical expansion, allowing the laboratory to broaden its footprint and reach more individuals in need of its crucial testing services. This move aligns with Avalon’s overarching strategy of tapping into unique roll-up opportunities within the laboratory testing and services market, which is characterized by its fragmented nature.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, highlighted the strategic significance of this acquisition. He emphasized, “Our strategy is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services.” (22)
The aim is to identify laboratories with outstanding performance, proven revenue track records, and specialized advantages within niche markets. Through the integration of LSM’s operational experience and infrastructure, Avalon anticipates substantial synergies that will drive revenue growth and expand market share, solidifying its position as a key player in the laboratory services sector.
As the healthcare landscape continues to evolve, the role of laboratory testing in enabling accurate diagnostics, personalized treatment plans, and preventive care cannot be understated. The acquisition of DE Labs not only reflects Avalon GloboCare Corp. (Nasdaq: ALBT)’s commitment to innovation and expansion but also its dedication to contributing to advancements in healthcare delivery and patient outcomes.
Avalon GloboCare Corp. (Nasdaq: ALBT)’s acquisition of DE Laboratory LLC represents a pivotal move within the laboratory testing and services sector. This strategic decision capitalizes on the laboratory’s impressive track record, offering a wide spectrum of testing services, and positions Avalon for substantial growth. With an eye towards geographical expansion and synergistic collaboration, Avalon is poised to make a lasting impact on the healthcare industry, driving innovation and excellence in diagnostics and testing services. (22)
AVALON GLOBOCARE CORP. (NASDAQ: ALBT)’S STRATEGIC INVESTMENT PAYS OFF: LSM RECORDS $14.7 MILLION REVENUE AND $6.3 MILLION NET INCOME (1)
Image Source (11)
Avalon GloboCare Corp. (NASDAQ: ALBT) recently announced its financial results for Laboratory Services MSO, LLC (LSM) for the twelve months ending December 31, 2022. The company, headquartered in Freehold, New Jersey, reported impressive figures, with LSM achieving a revenue of $14.7 million and a net income of $6.3 million during the period. (1)
The financial highlights for LSM in 2022 demonstrate its strong performance and profitability. Avalon GloboCare Corp. (NASDAQ: ALBT)’s strategic investment in LSM, acquiring a 40% interest in February 2023, has been validated by these results. The collaboration with LSM, a premier clinical diagnostics and reference laboratory based in Costa Mesa, California, has proven to be a successful endeavor.
LSM offers an extensive range of diagnostic tests, including drug testing, toxicology, pharmacogenetics (PGx), as well as general blood work, anatomic pathology, and other specialized services. With its quick turnaround times and state-of-the-art facility, LSM has built a stellar reputation for customer service satisfaction.
David Jin, M.D., Ph.D., President, and Chief Executive Officer of Avalon GloboCare, expressed satisfaction with LSM’s financial performance, emphasizing the company’s goal to further grow LSM’s top and bottom line. Leveraging LSM’s expertise and infrastructure, Avalon GloboCare plans to capitalize on the highly fragmented market for laboratory testing and services by targeting laboratories with exceptional performance and niche-market advantages. The aim is to achieve significant synergies through a strategic rollup approach.
The future looks promising for Avalon GloboCare Corp. (NASDAQ: ALBT) and LSM, as their 40% profit-sharing arrangement with LSM is expected to result in significant future cash flow to the company. With a strong focus on expanding LSM’s operations and leveraging its experience and infrastructure, Avalon GloboCare aims to create further success within the clinical diagnostics and reference laboratory sector. (1)
LSM’s commitment to excellence and its broad portfolio of diagnostic tests, combined with Avalon GloboCare’s strategic vision, position the partnership for continued growth and success. With over 600,000 tests completed since its inception and two operational locations in California, LSM is well-positioned to make a lasting impact in the industry.
Avalon GloboCare Corp. (NASDAQ: ALBT) continues to make strides as a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. The company remains dedicated to driving growth and achieving synergies within the laboratory testing and services market. With its focus on strategic investments and the strong performance of LSM, Avalon GloboCare Corp. (NASDAQ: ALBT) is a company to watch closely as it navigates the rapidly evolving landscape of the healthcare industry. (1)
Avalon GloboCare Corp. (NASDAQ: ALBT) recently announced a significant agreement with Qi Diagnostics Limited (Qi Diagnostics). This agreement grants Avalon exclusive distribution rights to market Qi Diagnostics’ groundbreaking KetoAir breathalyzer device and associated accessories, including future models. The distribution will cover North America, South America, the U.K., and the European Union. KetoAir functions as a companion diagnostic and monitoring device for ketogenic dietary management and will initially focus on the diabetes reversal and weight management markets. (13)
Image Source (15)
Qi Diagnostics is a renowned medical device company specializing in the development and manufacturing of proprietary Volatile Organic Compound (VOC) nanosensor-based in vitro diagnostic and screening devices. Their latest innovation, KetoAir, combines a breathalyzer with artificial intelligence (AI)-powered nutritionist consultation, providing invaluable support for ketogenic health management. The device has received approval from the United States Food and Drug Administration.
Image Source (16)
In addition to the distribution agreement, Avalon GloboCare Corp. (NASDAQ: ALBT) and Qi Diagnostics have plans for a collaborative effort to co-develop a breathalyzer device aimed at screening and early detection of lung cancer. The companies will share joint ownership of any intellectual property resulting from this co-development.
Expressing his enthusiasm about the partnership, Dr. David Jin, President and CEO of Avalon GloboCare, stated, “We are very excited to partner with Qi Diagnostics to exclusively distribute KetoAir in key markets. Our initial focus will be on diabetes reversal and obesity management. Scientific evidence has increasingly demonstrated that nutritional ketosis is an effective and sustainable approach for reversing diabetes and managing weight. A properly implemented ketogenic diet has been clinically proven to lower blood sugar, enhance insulin sensitivity, and reduce inflammation.” (13)
Dr. Jin further emphasized the significance of KetoAir, stating, “KetoAir is the first breathalyzer on the market that combines an AI-powered nutritionist with a nanosensor-based breathalyzer for ketogenic health management. It detects and quantifies acetone levels in the breath, allowing users to monitor their ketosis state while receiving 24/7 nutritional advice. We are eager to bring KetoAir to the market and assist individuals with diabetes and weight management needs.” (13)
Although the parties intend to finalize a definitive agreement regarding the terms and pricing, there is no guarantee that such an agreement will be reached or deemed acceptable to Avalon GloboCare Corp. (NASDAQ: ALBT). Nonetheless, the collaboration between Avalon GloboCare and Qi Diagnostics holds great promise for advancing the field of ketogenic health management and potentially revolutionizing the way diabetes and weight management are approached. (13)
AVALON GLOBOCARE CORP. (NASDAQ: ALBT) SECURES 16 PATENTS FOR REVOLUTIONARY MEDICAL TECHNOLOGIES (17)
Image Source (18)
valon GloboCare Corp. (NASDAQ: ALBT) has recently announced the issuance of a key U.S. patent by the United States Patent and Trademark Office (USPTO). The patent, numbered 11,555,060 and titled “QTY Fc Fusion Water Soluble Receptor Proteins,” was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT). This significant achievement expands Avalon’s intellectual property portfolio, showcasing its commitment to advancing medical technologies. (17)
The granted patent encompasses the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. At the core of this breakthrough is the “QTY Code,” a revolutionary technology developed in collaboration with MIT. This innovative platform has the remarkable ability to transform water-insoluble transmembrane receptor proteins into water-soluble proteins, significantly enhancing the solubility of designer peptides and proteins. As a result, the repertoire of selected therapeutic targets against cancers and other diseases is expanded, opening new avenues for medical advancements.
Dr. David Jin, President and Chief Executive Officer of Avalon GloboCare Corp. (NASDAQ: ALBT), expressed his satisfaction with the patent issuance, highlighting the company’s ongoing commitment to intellectual property development. With a total of 16 jointly filed patent applications, Avalon has established fruitful collaborations with esteemed partners, including top-tier universities, renowned research centers, and leading developers in the field. This strong portfolio reinforces Avalon’s position as an innovative contributor to medical advancements.
The QTY code protein design platform, developed in conjunction with Professor Shuguang Zhang’s laboratory at MIT, offers a transformative solution for working with water-insoluble proteins found within cellular membranes. By rendering these proteins water-soluble, the QTY technology enables their utilization in numerous clinical applications. Notably, soluble, antibody-like cytokine/chemokine decoy receptors derived through the QTY protein design hold great potential in various areas, including mitigating the “cytokine storm” associated with certain conditions and broadening the range of therapeutic targets addressable by advanced therapies. (17)
Image Source (19)
Dr. Jin concluded by emphasizing Avalon GloboCare Corp. (NASDAQ: ALBT)’s commitment to innovation and collaboration. In addition to the recently granted patent, the company has also made notable strides in other areas. For instance, Avalon GloboCare Corp. (NASDAQ: ALBT) has plans for a collaborative effort with Qi Diagnostics to co-develop a breathalyzer device aimed at screening and early detection of lung cancer. This collaboration will result in joint ownership of any intellectual property arising from the co-development, further highlighting Avalon’s dedication to advancing medical technologies and improving patient outcomes. (8)
“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,” Dr. Jin.(35)
AVALON GLOBOCARE’S LABORATORY SERVICES MSO SIGNS EXCLUSIVE IN-NETWORK LAB SERVICES AGREEMENT PROVIDING SIGNIFICANT EXPANSION OPPORTUNITY INTO 21 STATES
MSA Signed with GeneX Laboratory, an In-Network Laboratory Licensed in Multiple States Including Medicare and Medicaid
Laboratory Services MSO will be the Exclusive Testing Provider for Toxicology Testing, Genetic Testing and Others
FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has signed an exclusive Master Service Agreement (“MSA”) with GeneX Laboratory Professional Corp. (“GeneX”). Avalon owns a 40% interest in LSM.
Genex is a CLIA-certified and CAP-accredited laboratory located in Orange County, California that has been dormant and seeking a partner to utilize their valuable license networks. GeneX has licenses with major providers such as Aetna California, Anthem BC of California, United Health Care, Cigna, Noridian Medicare, TRICare West, and Medicaid in 21 states, including Alaska, Alabama, Arizona, California, Colorado, Idaho, Indiana, Iowa, Kentucky, Mississippi, Maine, Montana, Nebraska, New Mexico, North Dakota, Ohio, Oklahoma, Oregon, South Carolina, Texas and Washington. GeneX offers a range of high- quality testing, including Liquid Chromatography-Mass Spectrometry (LC-MS) drug testing, genetic testing, urinary testing and COVID-19 PCR testing. Those tests will now be performed utilizing the LSM infrastructure and resources providing significant expansion opportunity for LSM to perform services through in-network insurance providers previously unavailable.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, “This agreement is a key step in expanding LSM’s service offering to customers and providing them access to refer business in-network. GeneX provides top-tier, comprehensive laboratory testing services and works with major providers in addition to Medicaid in 21 states. This further expands our geographic testing footprint and should result in significant revenue for Avalon.”
“Our strategy is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. We continue to target laboratories with exceptional performance, positive revenue track records and niche-market advantages. By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market shares,” concluded Dr. Jin.
AVALON GLOBOCARE PROVIDES UPDATE ON NEW COMMERCIAL STRATEGY
Company Continues to Implement Major Change in Strategy Focused on Acquiring and Operating Accretive Revenue Generating Laboratories and Related Commercialized Products
Company Plans on Developing and Delivering Innovative, Transformative, Precision Diagnostics, Genetic Testing and Clinical Laboratory Services
FREEHOLD, N.J., July 10, 2023 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today provided the following letter to shareholders from the Company’s President and CEO, David Jin, M.D., Ph.D.:
“We are excited to provide an update on our new commercial strategy focused on laboratory acquisitions and diagnostics. Avalon is dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Our evolving strategy involves acquiring ownership or license rights to precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, share ownership structures or distribution rights. We intend to play a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. As a first major step into the laboratory market, we acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), which closed in February 2023. LSM generated revenue of $14.7 million and net income of $6.3 million in 2022. In turn, we believe our profit-sharing arrangement with LSM will result in significant future cash flow to Avalon. Since the acquisition, LSM has executed on its growth plan and has expanded their service offering to customers seeking to utilize providers within their insurance network. In addition, they have continued to evaluate additional accretive acquisitions.
Our goal is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with strong financial track records and niche-market advantages, we believe we can effectively leverage LSM’s experience and infrastructure to achieve significant synergies with respect to revenue growth and market share.
Additionally, LSM is focused on commercialization of genetic-based proprietary testing. The first area of focus in this area is confirmatory genetic testing during toxicology screening and genetic testing to screen for addictive predisposition. LSM plans to focus on diagnostic testing utilizing proprietary technology to deliver precise genetic-driven results.
During 2023, we also secured exclusive distribution rights and are making rapid progress towards commercialization of the KetoAir™ breathalyzer device and related accessories, including current and future models, in North America, South America, the U.K. and the European Union. KetoAir™ functions as a monitoring device for ketogenic dietary management and will initially target the diabetes reversal and weight management markets. KetoAir™ uses an AI nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management, which has been approved by the United States Food and Drug Administration. We had a successful pilot launch and exhibition of the KetoAir™ breathalyzer in this year’s KetoCon conference in Austin, Texas which was held in April 2023. Currently, we are evaluating options for commercialization, including identifying distribution partners or distributing KetoAir™ ourselves.
Regarding the R&D front, we are focused on bringing forward intellectual property through joint patent filings with the Massachusetts Institute of Technology (MIT). We completed a sponsored research and co-development project with MIT led by Professor Shuguang Zhang as Principal Investigator. Using the unique QTY code protein design platform, six water-soluble variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective cytokines. We look forward to advancing the intellectual property associated with this program by continuing to prosecute our joint patent applications.
We believe 2023 will be a pivotal year in the company’s history as we laid the foundation over the past few years to accomplish major achievements and successes in the coming year,” concluded Dr. Jin.
AVALON GLOBOCARE ANNOUNCES CLOSING OF STRATEGIC INVESTMENT IN LABORATORY SERVICES MSO, A LEADING CLINICAL DIAGNOSTICS AND REFERENCE LABORATORY COMPANY
Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement
Adds Strong Clinical Synergies to Existing Avalon Portfolio
Marks Launch of New Roll-Up Strategy Targeting Toxicology and Pharmacogenetic Laboratories
FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has acquired a 40% interest in Laboratory Services MSO, LLC (“LSM”), a premier clinical diagnostics and reference laboratory. Headquartered in Costa Mesa, California, LSM provides a broad portfolio of diagnostic tests including drug testing, toxicology, pharmacogenetics, and a broad array of test services, from general bloodwork to anatomic pathology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. LSM has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory. It has also developed a premier reputation for customer service satisfaction and fast turnaround time in the industry. LSM has completed over 600,000 tests since inception and currently has two operational locations in California.
Total consideration for the transaction was $21 million, consisting of (i) $9 million in cash, (ii) $11 million in shares of the Company’s Series B preferred stock, which are convertible into shares of the Company’s common stock at a fixed conversion price of $3.78 per share, and (iii) $1 million in cash payable on February 9, 2024. The preferred shares will be restricted from conversion for 12 months and thereafter will have leak-out provisions restricting conversion to only 10% of total holdings. In addition, the seller is also eligible, under the terms set forth in the purchase agreement, to receive certain earnout payments upon achievement of certain operating results, which may be comprised of up to $10,000,000 of which (iv) up to $5,000,000 will be paid in cash and (v) up to $5,000,000 will be paid pursuant to the issuance of the number of shares of Company common stock valued at $5,000,000, calculated using the closing price of the Company’s common stock on December 31, 2023.
In connection with the transaction, the parties entered into an operating agreement, whereby the Company will receive a pro rata percentage of LSM’s net income. The Company also has an exclusive option for nine months to purchase an additional 20% of LSM for $6 million in cash and $4 million in additional shares of the Company’s Series B preferred stock.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, “We are excited to close this initial investment as a first step, and anticipate acquiring a controlling interest within the next nine months. Not only is this transaction expected to be accretive to our earnings, we believe it also adds strong clinical and roll-up synergies to the existing Avalon portfolio and future growth plan. By combining LSM’s established infrastructure with Avalon’s cutting-edge diagnostic and cellular immunotherapy platforms, it provides us with an established roadmap and framework in the context of integrating our CellTech/therapeutic programs with precision medicine.”
“Our goal is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with exceptional performance, positive revenue track record and niche-market advantage, we believe we can effectively leverage LSM’s experience and infrastructure to achieve significant synergies with respect to revenue growth and market shares,” concluded Dr. Jin.
A more complete description of the transaction will be included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (“SEC”), which will be available at the SEC’s website at www.sec.gov.
_____
AVALON GLOBOCARE (AVCO) – INVESTOR FORUM AT THE WORLD STEM CELL SUMMIT
Dr. David Jin, MD, PhD, a director and Chief Executive Officer of the Company and AHS. From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters. Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.
MENG LI
Chief Operating Officer, Secretary and Director
Ms. Li served on the Company’s board from October 2017 through July 2018 and was re-appointed in February 2019. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.
LUISA INGARGIOLA
Chief Financial Officer
Luisa Ingargiola has almost 20 years of experience in public company finance, compliance and capital markets oversight. She currently serves as Audit Chair of FTE Networks (FTNW) and Audit Chair of Electra Mecchanica (ECCTF). She has held various positions as Chief Financial Officer or Audit Chair with several public companies and has helped manage over $100 Million in financing. Ms. Ingargiola has helped guide the up-list of several OTC companies to NASDAQ or the NYSE. She graduated from Boston University with a Bachelor Degree in Business Administration and received her MBA in Health Administration from the University of South Florida.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY ALBT AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
DATS SEES 1,200 TO 2,500 NEW MEMBERS JOINING HABYTAT DAILY
THE COMPANY REPORTED THAT IT HAS PURCHASED 667,691 SHARES OF COMMON STOCK AT AN AVERAGE PRICE OF $0.5949 PER SHARE AS OF 5/31/2023 FROM IT’S $2 MILLION REPURCHASE PROGRAM AUTHORIZED IN JANUARY
We have a new low priced Nasdaq company that we want you to research right away.
This is a company that we have never profiled before that we want to be the first to bring to your attention.
This one is hovering around .50 and the chart shows that this one has moved on interest before.
Pull up DATS Immediately.
DatChat Inc. is a metaverse and social media company that not only focuses on protecting our privacy on our devices, but also protecting personal information after we have shared it with others. They believe an individual’s right to privacy should not end the moment they click “send”, and that we all deserve the same right to privacy online that we enjoy in our own living rooms. The flagship product, the DatChat Messenger & Private Social Network, is a privacy platform and mobile application that provides users the ability to communicate and share with the privacy and protection they deserve.
Their platform allows users to exercise control over their messages and posts, even after they are sent. Through their application, users can delete messages that they send on their own device and the recipients device as well. There is no set time limit within which they must exercise this choice. A user can elect at any time to delete a message previously sent to a recipients device. In addition, users can delete entire conversations at any time, making it like the conversation never even happened. Additionally, the application includes a screenshot protection system, which makes it virtually impossible for the recipient to screenshot a message or picture before it gets destroyed.
NEW COMMUNICATION PLATFORM
Until Now, no messaging platform allowed you to change the rights to your messages After You HIT SEND.
ANTI-SCREENSHOT
When “Anti-Screenshot” mode is enabled, DatChat’s proprietary technology completely prevents a phone’s ability to take a screenshot of the image on screen.
NUKE & SELF-DESTRUCT
Set your messages to Self-Destruct after a set number of views or length of time. Or Nuke an entire conversation from a recipient’s phone any time you want. Your conversation disappears without a trace!
HIDE IN PLAIN SIGHT
Encrypt secret photos behind a cover image. You can store this covered image in your Camera Roll, and only the cover will be visible.
WITHOUT A TRACE
When a message is destructed or deleted, it is completely gone forever.
POWERFUL PRIVACY
Messages stored on your device are encrypted specifically for you, and can never be opened on a device not associated with your unique account credentials.
FAST, SAFE & EASY
Our powerful features are easy to use and find in an intuitive interface that will let you get started immediately.
🚀🌐 Ready to explore the incredible world of the #metaverse? Don't miss out on reading this article by Darin Myman, CEO of @datchatapp!
Discover how AI is transforming the metaverse for everyone and bringing it to the masses 🙌🏼
— Habytat by Smarterverse (@habytat_io) June 14, 2023
They also own and run Habytat.
Habytat by SmarterVerse, a subsidiary of DatChat Inc., is a metaverse platform and privacy-first social network. By dramatically lowering the financial and technical barriers to entry to the metaverse, Habytat is democratizing access to the digital realm and giving users a remarkable opportunity to co-create community, business and life together. Built on SmarterVerse Holding’s patented privacy technology, Habytat grants users complete control over their data, creating a social network users can trust.
Habytat is an open mobile metaverse that offers users free NFT-deeded properties and houses in Geniuz City, the first residential area modeled after Miami’s Wynwood arts district. Users can visit art galleries, explore the town, interact with others, take selfies with famous landmarks, customize their properties and enjoy the experiences that its community has to offer.
Habytat’s metaverse offers an experience for first-time users and average consumers—the ability to step into the metaverse and experience the value it has to offer. Currently, the Company has provided free NFT-deeded properties to all users, with other releases soon to be launched.
DATCHAT LAUNCHES THE HABYTAT MOBILE METAVERSE FOR THE MASSES
Habytat Offers Free NFT Deeded Metaverse Property and Houses to Users
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)– DatChat Inc. (Nasdaq: DATS), today launches the initial version of its Habytat open mobile metaverse through its SmarterVerse, Inc. subsidiary. Habytat version 1.0 offers users free NFT deeded properties and houses in Geniuz City, the first residential area of the Habytat modeled after Miami’s Wynwood arts district. As of today, users can visit art galleries, explore the town, interact with others, take selfies with famous landmarks, customize their properties and enjoy the experiences that the Habytat has to offer.
Recognizing the high barrier to entry with existing metaverse platforms, Habytat’s mission is to democratize access through a variety of key offerings. By being available via mobile devices and offering free ownership of land and homes, Habytat breaks down obstacles that previously limited participation, such as the necessity for expensive gear such as VR headsets or metaverse properties. The development of more realistic looking content, daily rewards, games, and new utilities further enhance the user experience in an engaging way.
“Currently, most people have no idea what the metaverse is, what it does, what it looks like or how to get involved, which has impeded mass adoption by the average consumer. We saw a unique and timely opportunity to leverage our patents and develop new technology that hopefully leads to more people joining and seeing the value in the metaverse. Habytat offers all users free NFT deeded properties that will serve as a key to the new social media, unlocking interesting content, new utilities and access through both mobile devices and virtual reality,” stated Darin Myman, CEO of DatChat.
“The next generation of social media will change how we exchange, store, and control our information. Having the ability to delete or preserve your data will change the current data ownership model in favor of the consumer.”
Users can visit art galleries, walk around town, interact with others, take selfies with famous landmarks, customize their properties and enjoy the culture of Geniuz City. Version 2.0 of the Habytat is scheduled to launch in June of 2023, and will include a full virtual reality experience, AI Pets with an interactive dog park, a Music District, and much more.
“We have built a highly talented team of over fifty game developers, graphic artists and back-end developers that have worked tirelessly to create Habytat 1.0. This is just the beginning of the journey for us. We are very proud of Habytat, but the best is yet to come,” stated Gianfranco Lopane, President, Smarterverse, Inc.
The official in-world currency of the Habytat is the “Nirad,” which can be earned through participation on the DatChat Social Network+ or the Habytat and used to upgrade properties and experiences in the Habytat.
The Habytat is available as a free download for both iOS and Android. For more information, visit Habytat.io.
DATCHAT PUBLISHES STRONG GROWTH METRICS FOR ITS HABYTAT METAVERSE
Company sees 1,200 to 2,500 new members joining Habytat daily
New users receive free NFT deeded properties and houses; mobile app now available in the Apple App Store and Google Play
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)– DatChat (Nasdaq: DATS), a private messaging, social media and metaverse company, is pleased to announced that it has published its daily landowner statistics on the Habytat.com website to provide a transparent view of the community’s growth and progress. For the month of August 2023, the Company’s Habytat, reached over 45,000 users as of 08/08/23, adding between 1,200 to 2,500 new members daily. The Company launched Habytat version 1.0 in May 2023 and its soon-to-be-launched Version 2.0 will include a full VR experience, AI Pets with an interactive dog park, and a Music District.
“The growth of our community is a testament to the allure of our immersive digital landscape, the value proposition to our members, and the easy access to our metaverse straight from your mobile device,” said DatChat CEO Darin Myman. “Our developers are ramping up the offerings in Habytat and we know this will serve as a solid foundation as we see foresee mass adoption, which will allow us to capitalize on the growth by adding additional products in the coming months.”
Darin Myman has served as Chief Executive Officer and as a director of the Company since January 2016. Prior to DatChat, Mr. Myman was a co-founder and Chief Executive Officer of Wally World Media, Inc., a public company. He also has served as the Chief Executive Officer and a member of PeopleString’s board of directors since PeopleString’s inception. Mr. Myman developed extensive Internet skills through a variety of positions. He has executive management and founder experience having served as a co-founder and Chief Executive Officer of BigString Corporation, a publicly traded company, since October 2005. He also has corporate governance and board experience having served as a member of BigString’s board of directors since BigString’s inception. Prior to BigString, Mr. Myman was a co-founder and Chief Executive Officer of LiveInsurance.com, the first online insurance broker that pioneered the electronic storefront for large national insurance agencies. Prior to co-founding LiveInsurance.com, he served as a Vice President of the online brokerage services unit of Westminster Securities Corporation
PETER SHELUS
CTO
Peter Shelus is a co-founder of DatChat and has served as our Chief Technology Officer since January 2016. Mr. Shelus has over 10 years of ephemeral messaging and mobile video development experience. Mr. Shelus has been at the forefront of the secure messaging industry, having served as a lead engineer for one of the first ephemeral messaging platforms, “BigString,” where he helped develop the patented technology that became a cornerstone of self-destructing messaging. Mr. Shelus received a bachelor’s degree in computer science from Rutgers University, where he graduated with honors.
GABRIEL DANIELS
CIO
Gabriel Daniels has been our Chief Information Officer since March 2021. Since May 2019, Mr. Daniels has served as the Co-Founder, President & CEO of NGD Cybersecurity and Customer Service Consultants LLC, a Minority-Woman Owned and Veteran Owned Business providing high-level technical, cyber commissioning, customer service and project management consulting services for companies within the DHS 16 critical infrastructure. From April 2018 to April 2019, Mr. Daniels served as the Cybersecurity Program Manager at Chinook Systems, an engineering firm. From June 2017 to April 2018, Mr. Daniels worked as a Senior Information Assurance Manager at Navstar Inc., an Information Technology & Services firm. In addition, since December of 2017, Mr. Daniels has worked as an adjunct professor at Northern Virginia (NoVA) Community College and Lord Fairfax Community College, where he teaches classes such as introduction to telecommunications, cyberlaw, network attacks, computer crime and hacking, and computer applications and concepts. Mr. Daniels is a 15-year U.S. Army and Navy veteran. While serving in the Army, Mr. Daniels aided in the development of the Army’s Strategic Cybersecurity and Cyber’s Incident Handling Response Plans. Mr. Daniels holds a master’s degree in cybersecurity and a bachelor’s degree in marketing from the University of Maryland University College.
BRETT BLUMBERG
CFO
Mr. Blumberg has extensive experience in finance and accounting. He is a certified public accountant and has been a partner of the public accounting firm Jubran, Shorr & Company since 2015. Mr. Blumberg was a senior accountant at CohnReznick, LLP from 2013 – 2014. Prior to obtaining the CPA license Mr. Blumberg was a private banker at Wells Fargo and owned and operated a Mortgage Brokerage/Banking Company, Canyon Financial Group, LLC during the period of 2006 – 2012. He previously worked in recruitment and talent acquisition for accounting and finance firms from 2000 – 2006. Mr. Blumberg has a B.A. in economics and psychology from SUNY Binghamton.
GIANFRANCO LOPANE
Head of Business Development
Lopane serves as Head of Business Development in charge of the team responsible for revenue growth enablement within DatChat’s Social Network+, Metaverse, NFT, and blockchain initiatives. In his 20 years of experience, he has worked with startups as well as Fortune-500 companies like Nestle, Hertz, and XPO Logistics in different senior-level positions. Back in 2017 he started his career in the blockchain space and co-founded an advertising network company for the metaverse and by 2018 he founded Generiqo, the company that is currently helping dozens of companies to migrate to the blockchain space. In 2014 Gianfranco obtained his Master’s degree in Commerce and Marketing (MCom) from EUDE Business School in Madrid, Spain.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY DATS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
LPTV REPORTED A 6% QUARTER-OVER-QUARTER INCREASE IN REVENUE, REACHING $5.7 MILLION FOR THE FISCAL THIRD QUARTER
B. RILEY SECURITIES INITIATES COVERAGE ON LOOP MEDIA, INC. (NYSE AMERICAN: LPTV) WITH A $5.00 TARGET
LPTV REVOLUTIONIZES BUSINESS ENTERTAINMENT WITH CUTTING-EDGE AI TECHNOLOGY
Hello Everyone,
We have another low priced profile that is worthy of your attention this week.
This is a company that you are going to want to research right away.
Pull up LPTV immediately.
The world of advertising is undergoing a potential transformation as Digital Out-of-Home (DOOH) advertising Connected (CTV) gains prominence across a range of industries and locations. Bars/Restaurant Franchises, Universities, Fitness Centers, Malls, Retail Stores, and Hotels are among the sectors embracing this innovative approach. (4)
Traditional static billboards and posters are being replaced by captivating digital screens, providing immersive and interactive experiences. DOOH / CTV ads, featuring animated images and videos, effectively engage audiences in real-time with impactful content. The global DOOH market is projected to reach USD $58.67 billion by 2030, driven by digital ad inventory and the integration of dynamic screens in public spaces. (3)
Programmatic DOOH advertising is also emerging as a key development, streamlining the ad buying process for brands. Personalized and location-based content further enhances audience engagement, leaving a memorable impression. Loop Media, Inc. (AMEX: LPTV) is one of the companies to keep an eye on in the DOOH advertising landscape, offering a multichannel streaming platform with mesmerizing music videos and branded entertainment channels. Their innovative approach caters to the advertising needs of Bars/Restaurant Franchises, Universities, Fitness Centers, Malls, Retail Stores, and Hotels, transforming customer experiences in these locations. (4)
LOOP MEDIA, INC. (AMEX: LPTV) EXPANDS REVENUE STREAMS, CAPTURES MARKET WITH DIRECT AD SALES APPROACH(6)
Image Source (18)
Loop Media, Inc. (AMEX: LPTV) is a multichannel digital video platform media company that has strategically positioned itself in the market to overcome challenges and drive growth. By leveraging its proprietary tech stack and extensive content library, Loop Media curates and distributes short-form videos to out-of-home (OOH) locations, including dining establishments, hospitality venues, retail stores, and convenience stores, creating engaging experiences for customers in these settings. (6)
Despite recent headwinds in the overall digital advertising market, Loop Media has demonstrated its resilience and commitment to continued growth. The company reported a significant increase in active Loop Players/Partner Screens across its platform, with over 57,000 active units by the end of March 2023, a growth rate of 5.4 times compared to the previous year. This expansion validates the appeal of Loop Media’s content and technology stack, contributing to positive operating results. (6)
To overcome market challenges, Loop Media has implemented cost-cutting measures while maintaining its dedication to growth. The company has focused on efficiency and made adjustments across various aspects of its business, including labor reduction and content license renegotiations. These efforts have resulted in stronger content license margins and improved overall margins, positioning Loop Media for increased profitability. (6)
The company’s distribution footprint has played a crucial role in its success. With an estimated monthly video impressions viewed of over 2 billion, Loop Media’s extensive reach allows businesses to engage with a vast audience. Moreover, Loop Media’s business model, which provides free streaming TV to businesses through the Loop Player, offers a resilient distribution growth strategy that sets it apart from subscription-based models. The company’s strong track record in digital advertising and its role as a digital advertising sales service provider for third-party partners further reinforces its potential for growth. (6)
Loop Media has also expanded its revenue streams by venturing into direct ad sales, beyond its traditional focus on programmatic digital advertising. This strategic move positions the company to capture higher cost-per-thousand ad impressions (CPMs) for its advertising inventory, attracting companies seeking to advertise in digital media outside the home. With a dedicated direct sales team, Loop Media expects to make a greater impact in the market and reduce dependency on programmatic advertising demand. (6)
Additionally, Loop Media has taken steps to enhance margins by optimizing its content mix on the O&O Network and renegotiating content licenses. These efforts will lead to improved margins for non-music video channels, further strengthening the company’s financial position. (6)
Loop Media’s customer acquisition strategy, primarily driven by digital marketing and an affiliate network, allows the company to defer payment until customers are successfully acquired. This approach optimizes cost management and aligns with Loop Media’s commitment to efficiency.(6)
Loop Media, Inc. (AMEX: LPTV) stands as a resilient and forward-thinking digital video platform media company, utilizing MarTech to generate revenue and provide services. With its expansive content library, strong distribution network, and strategic initiatives, Loop Media has positioned itself for continued growth and success in the dynamic digital advertising landscape.(6)
LOOP MEDIA, INC. (NYSE AMERICAN: LPTV) REVOLUTIONIZES BUSINESS ENTERTAINMENT WITH CUTTING-EDGE AI TECHNOLOGY… (20)(21)
Image Source (22)
Loop Media, Inc. (NYSE American: LPTV) has recently made significant strides in the industry through two transformative strategic partnerships. Collaborating with AssemblyAI and Pypestream, Loop Media is harnessing the power of Artificial Intelligence (AI) to enhance ad assurance and deliver personalized content recommendations, revolutionizing the way businesses engage with their audiences. (20)(21)
AI-Powered Brand Safety Solution Loop Media, Inc. (NYSE American: LPTV)’s partnership with AssemblyAI brings forth an innovative AI-powered Brand Safety Solution, setting new standards for brand integrity and protecting venues from inappropriate or competitive advertisements. This cutting-edge technology marks a significant advancement for Loop Media, as it offers state-of-the-art ad detection techniques at scale to its clients and partners, without incurring additional costs. (20) Challenges in Ad-Supported Streaming: In the past, businesses faced challenges in maintaining their reputation while utilizing free ad-supported streaming television channels. The lack of control over the content displayed in ads burdened businesses with potential risks. However, Loop Media, Inc. (NYSE American: LPTV)’s Brand Safety Layer now addresses this concern, providing businesses with the assurance of safeguarding their reputation while streaming advertisements. (20) Enhanced Ad Assurance with AI: Bob Gruters, Chief Revenue Officer of Loop Media, Inc. (NYSE American: LPTV), emphasizes the significance of preserving a business’s reputation and points out that accepting ads without control is no longer acceptable. The introduction of the AI-Powered Brand Safety Layer empowers Loop Media to seamlessly integrate advanced AI models with any demand-side platform (DSP). In collaboration with AssemblyAI, Loop Media can now analyze speech, detect unsuitable content, and identify competitive keywords in the advertisements streamed on Loop TV channels. (20) Leveraging AssemblyAI’s Pioneering AI Technology: AssemblyAI’s latest state-of-the-art AI research empowers Loop Media’s Brand Safety Solution with production-ready, secure, and scalable AI models. The integration of AssemblyAI’s advanced AI technology enables Loop TV to efficiently ensure brand safety and align advertisements with the brand values of venues. (20) AI-Powered Content Recommendations In another game-changing collaboration, Loop Media, Inc. (NYSE American: LPTV) partners with Pypestream to introduce an AI-driven approach to curated entertainment in business venues. Leveraging Pypestream’s proprietary technology, Loop Media aims to revolutionize the customer experience by providing personalized content recommendations based on AI-generated information. (21) Enhancing Customer Experiences with AI: With over 2 billion monthly video views across various venues, Loop Media, Inc. (NYSE American: LPTV)seeks to transform the way customers experience entertainment. The partnership with Pypestream empowers Loop Media to leverage AI, ensuring that the right content is displayed at the right time for the right audience in each location. (21) Empowering Business Venues with Personalized Content: Pypestream’s AI technology, known for building high-impact and immersive customer experiences, extends to various business venues, including bars, restaurants, retail stores, doctors’ offices, and college campuses. Each venue now has the power to curate its ideal entertainment experience, tailored to its unique audience. (21) Introducing the Channel Recommender: Originally envisioned for support automation, the collaboration with Pypestream has evolved into driving user growth and retention. The newly released “Channel Recommender,” integrated into the Loop Media Player’s digital assistant/chatbot, enhances the customer experience by providing personalized content recommendations to viewers. (21)
Loop Media, Inc. (NYSE American: LPTV)’s strategic partnerships with AssemblyAI and Pypestream underscore the company’s commitment to harnessing cutting-edge AI technology for enhanced ad assurance and personalized content delivery. By embracing AI’s capabilities, Loop Media empowers businesses to deliver secure, engaging, and tailored entertainment experiences to their audiences. Positioned at the forefront of innovation, Loop Media is redefining how businesses engage with their customers through AI-driven solutions, revolutionizing the future of business entertainment.
Keep reading to see why Loop Media, Inc. (NYSE American: LPTV) deserves a top-spot on your daily watchlist…
LOOP MEDIA, INC. (NYSE AMERICAN: LPTV) DELIVERS FISCAL THIRD QUARTER 2023 FINANCIAL RESULTS AND ACHIEVES APPROXIMATELY 20% SG&A EXPENSE REDUCTION TARGET… (23)
Loop Media, Inc. (NYSE American: LPTV) has released its financial and operating results for the fiscal third quarter that concluded on June 30, 2023. The company’s performance demonstrates resilience in challenging market conditions and strategic initiatives to enhance cost efficiencies. (23)
Fiscal Q3 2023 Highlights Loop Media, Inc. (NYSE American: LPTV) reported a revenue of $5.7 million for the fiscal third quarter of 2023.
The gross profit reached $1.8 million, with a gross margin of 31.8%.
Adjusted EBITDA, a non-GAAP financial measure, was $(3.7) million.
The company operated 34,898 Quarterly Active Units (QAUs) on its O&O Platform and boasted a total of around 37,000 screens across Partner Platforms by June 30, 2023.
Operational Insights Jon Niermann, CEO of Loop Media, Inc. (NYSE American: LPTV), expressed satisfaction with the company’s fiscal third-quarter performance, surpassing forecasted expectations across various metrics. Loop Media not only achieved the projected approximate 20% reduction in Selling, General, and Administrative (SG&A) expenses but also exceeded forecasts for revenue and gross profit margin. Niermann highlighted the expansion of the Partner Platform as a notable accomplishment during the quarter.
The company tackled headwinds in advertising demand that surfaced in 2023 by revisiting its cost structure and growth strategy. Loop Media focused on reducing costs and increasing efficiencies, including the strategic elimination of certain positions. Despite this, the company remained committed to its lean organizational approach and managed to absorb the responsibilities of eliminated personnel within existing roles.
Loop Media, Inc. (NYSE American: LPTV) strategically slowed down growth in its O&O Platform’s QAUs during the quarter, aiming to prioritize distribution in key advertising markets and desirable out-of-home locations. This approach contributed to a 7% quarter-over-quarter increase in QAUs. The company also reduced its presence in less favorable out-of-home locations to optimize net distribution growth.
The company’s Partner Platform demonstrated strong growth, with screens increasing from 24,000 to 36,000, marking a 50% surge by the end of Q3. The strategy centered on aggressive growth in the Partner Platform while refining distribution efforts in key markets and geographies.
Financial Performance Despite challenges in the macroeconomic environment and advertising headwinds, Loop Media reported a 6% quarter-over-quarter increase in revenue, reaching $5.7 million for the fiscal third quarter. This growth was driven by efforts to educate advertising partners on Loop Media’s role in the Connected Television (CTV) and digital video landscape.
Gross profit for the quarter was $1.8 million, resulting in a gross margin of 31.8%. While gross margin decreased slightly, it was attributed to shifts in revenue mix and incremental licensing costs.
Loop Media, Inc. (NYSE American: LPTV) achieved a reduction in SG&A expenses (excluding stock-based compensation and depreciation and amortization), amounting to $6.3 million for the fiscal third quarter. This reduction was achieved through a combination of strategies, including a decrease in marketing spend and other operating expenses.
Looking Ahead Loop Media, Inc. (NYSE American: LPTV)’s strategic approach to prioritize growth in favorable markets, combined with expanding Partner Platform offerings, positions the company for future success. Despite the ongoing challenging macroeconomic environment, Loop Media remains optimistic about its ability to capitalize on market recovery and increased advertising spend potential in 2023 and beyond.
The company’s commitment to refining its distribution strategy and leveraging its unique position in the streaming television industry highlights the company’s dedication to delivering engaging content to a wide and receptive audience.
Loop Media, Inc. (NYSE American: LPTV)’s fiscal third-quarter performance underscores its adaptability and strategic prowess in the ever-evolving streaming television landscape. With a commitment to cost efficiencies, expansion in strategic partnerships, and a focus on optimizing distribution, Loop Media continues to pave the way for growth and innovation in the industry.
Keep reading to learn more about why Loop Media, Inc. (NYSE American: LPTV) needs your immediate attention…
LOOP MEDIA, INC. (AMEX: LPTV)
7 REASONS WHY LOOP MEDIA, INC. (AMEX: LPTV) IS POISED FOR MEANINGFUL GROWTH.
#1. B. RILEY SECURITIES INITIATES COVERAGE ON LOOP MEDIA, INC. (NYSE AMERICAN: LPTV) WITH A $5.00 TARGET
Source (19)
Leading financial services firm B. Riley Securities has announced the initiation of coverage on Loop Media, Inc. (NYSE American: LPTV) with a bullish rating and a 12-month target of $5 per share. The move comes as Loop Media, Inc. (NYSE American: LPTV) is poised to benefit from the ongoing shift of advertising budgets towards digital options. B. Riley Securities predicts strong revenue growth for DOOH advertising in the coming years, positioning Loop Media for success. Shares of (LPTV) opened at $1.97 on 8/7/2023, according to Barchart.com, which would suggest over 153% in potential upside according to the $5.00 target set by B. Riley Securities. (19)(1) While the advertising industry faces macroeconomic uncertainty, B. Riley Securities considers this period as a potential bottom for Loop Media’s average revenue per user (ARPU). The company is strategically capitalizing on this opportunity to further penetrate an untapped addressable market and increase its share of DOOH venues. Loop Media’s position within the industry should strengthen as advertising demand recovers, DOOH venues gain a larger portion of advertising budgets, and operating leverage becomes more favorable. (19)
GROWTH DRIVERS AND MARKET POTENTIAL:
The outlook for digital out-of-home advertising is highly promising, with digital spending projected to outpace physical spending in the coming years. Loop Media, along with other players in the industry, has a significant growth opportunity, especially as consumers increasingly accept advertising in exchange for desired content, even outside traditional settings. B. Riley Securities estimates a vast untapped domestic addressable market of at least 3.2 million locations encompassing retail stores, gas stations, restaurants, bars, salons, gyms, and convenience stores. Loop Media’s current presence in only approximately 100,000 locations indicates substantial room for expansion, particularly as the company focuses on top 20 demographic markets. (19)
DUAL GROWTH STRATEGY AND POSITIVE AEBITDA PROJECTION:
Loop Media employs a dual growth strategy to drive penetration in the market. The company provides Loop Players, integrating them with existing audio/video systems, and grants access to its expansive content library featuring over 200 channels. Additionally, Loop Media’s Partner Program allows the utilization of installed networks of consumer-facing screens, such as retail point-of-sale and gas station pumps, to accelerate market penetration. Based on its screen base growth, conservative recovery in advertising spending, and improving margins from content mix shift, Loop Media is projected to achieve positive Adjusted EBITDA (AEBITDA) in the fourth quarter of 2024.(19)
ATTRACTIVE VALUATION AND GROWTH POTENTIAL:
Considering the projected revenue growth rate for Loop Media, Inc. (NYSE American: LPTV) in CY24, which is over 8 times the peer group average, B. Riley Securities asserts an attractive valuation for the company. Loop Media’s premium EV/S multiple relative to the peer group is justified by its expected pivot to positive AEBITDA. Additionally, as investor awareness of the DOOH advertising opportunity increases, Loop Media is expected to benefit, as evidenced by a private peer company’s recent financing round at an 18x LTM revenue multiple. (19)
B. Riley Securities’ initiation of coverage on Loop Media, Inc. (NYSE American: LPTV), Inc. highlights the company’s potential for significant growth in the digital out-of-home advertising market. (19)
#2. DISRUPTIVE MARKET OPPORTUNITY: LOOP MEDIA, INC. (NYSE AMERICAN: LPTV) OPERATES IN THE DIGITAL OUT-OF-HOME (DOOH) INDUSTRY, WHICH IS EXPERIENCING STRONG GROWTH AND OFFERS SIGNIFICANT MARKET POTENTIAL. (6)
LOOP MEDIA, INC. (AMEX: LPTV): UNLOCKING THE POTENTIAL OF THE DIGITAL OUT-OF-HOME INDUSTRY
In today’s fast-paced digital world, Loop Media, Inc. (AMEX: LPTV) has positioned itself at the forefront of a disruptive market opportunity. As an innovative player in the digital out-of-home (DOOH) industry, Loop Media is capitalizing on a thriving sector that offers substantial growth potential.
In this section of the report we delve into the exciting landscape of the DOOH industry and explore how Loop Media is poised to revolutionize the way we engage with digital content in out-of-home environments.(6)
DISRUPTIVE MARKET OPPORTUNITY:
The DOOH industry is expected to experience remarkable growth, driven by the growing demand for engaging and dynamic content in public spaces.
Traditional static billboards are giving way to digital displays, offering advertisers and content creators unparalleled opportunities to captivate audiences.
Loop Media, Inc. recognizes the potential in this evolving market and has strategically positioned itself as a key player in delivering high-quality content across various venues, including restaurants, retail stores, fitness centers, and more. (6)
GROWTH POTENTIAL:
The growth prospects within the DOOH industry are staggering. With the increasing prevalence of digital screens in public spaces, advertisers are seeking innovative ways to reach their target audiences effectively.
Loop Media’s digital content platform enables seamless integration of captivating videos, music, and interactive experiences, revolutionizing how brands connect with consumers. By leveraging advanced analytics and targeting capabilities, Loop Media empowers advertisers to deliver tailored and engaging content to specific demographics, maximizing their marketing efforts and ensuring optimal viewer engagement. (6)
UNLEASHING CREATIVITY:
Loop Media’s comprehensive content library spans a diverse range of genres, including music videos, sports, lifestyle, and more. This extensive collection enables businesses to curate immersive experiences that resonate with their target customers.
From enhancing the ambiance in a trendy café to entertaining guests at a fitness center, Loop Media’s vast content catalog offers unparalleled flexibility and creative freedom to captivate audiences and leave a lasting impression. (6)
STRATEGIC PARTNERSHIPS:
Loop Media, Inc. has forged strategic partnerships with leading brands, content creators, and venue owners, establishing a robust ecosystem that amplifies its market reach.
These collaborations provide Loop Media with access to exclusive content, ensuring a steady stream of compelling material to captivate audiences. By partnering with key industry players, Loop Media demonstrates its commitment to delivering top-notch experiences that exceed customer expectations. (6)
As the DOOH industry continues to thrive, Loop Media, Inc. (AMEX: LPTV) stands out as one of the companies to keep an eye on, reshaping the way digital content is experienced in out-of-home environments. With its extensive content library, advanced targeting capabilities, and strategic partnerships, Loop Media offers a unique value proposition to advertisers, venue owners, and consumers alike.
By unlocking the potential of the DOOH industry, Loop Media is set to redefine the way we engage with digital content, creating captivating experiences that leave a lasting impact. Stay tuned as Loop Media, Inc. (AMEX: LPTV) paves the way for the future of digital out-of-home entertainment. (6)
#3. ENGAGING CONTENT LIBRARY: LOOP MEDIA, INC. (AMEX: LPTV) HAS A VAST LIBRARY OF LICENSED AND ORIGINAL CONTENT, PROVIDING A COMPELLING AND IMMERSIVE ENTERTAINMENT EXPERIENCE FOR AUDIENCES. (6)
Image Source (11)
MUSIC LABEL PARTNERSHIPS AND NON-MUSIC CONTENT COLLABORATIONS: LOOP MEDIA, INC. (AMEX: LPTV): REDEFINING THE POWER OF ENGAGING CONTENT
Loop Media, Inc. (AMEX: LPTV) is revolutionizing the digital entertainment landscape with its captivating and diverse content library. With a strong focus on immersive and engaging experiences, Loop Media has emerged as a prominent player in the industry. In this section of the report, we explore the value proposition of Loop Media and how its extensive content library, coupled with strategic partnerships, sets the stage for an exciting entertainment journey.(6)
A DYNAMIC CONTENT COLLECTION:
Loop Media boasts an extensive library of licensed and original content across various genres and interests. From music videos, films, and sports highlights to lifestyle content, Loop Media offers something for everyone.
By meticulously curating a diverse range of content, Loop Media ensures that audiences have access to an unparalleled entertainment experience. (6)
Image Source (15)
IMMERSIVE ENTERTAINMENT:
In today’s fast-paced digital era, Loop Media understands the importance of captivating and immersing audiences.
Whether it’s the latest music videos from popular artists or thrilling sports highlights, Loop Media’s content library delivers an immersive experience that keeps audiences coming back for more. (6)
DISCOVERING HIDDEN GEMS:
Loop Media’s content library goes beyond the mainstream, uncovering hidden gems and introducing audiences to emerging talent. By showcasing a mix of established artists and rising stars, Loop Media becomes a platform that not only entertains but also fosters discovery.
Audiences can explore new music, films, and other content that they may not have encountered elsewhere, providing an enriching and fulfilling entertainment journey. (6)
CUSTOMIZED EXPERIENCES:
Loop Media recognizes the importance of personalization in creating memorable experiences. With its extensive content library, Loop Media enables businesses to curate customized entertainment experiences tailored to their target audiences.
Whether it’s a restaurant, retail store, or fitness center, Loop Media’s flexible platform allows businesses to create an ambiance that resonates with their customers, enhancing the overall experience and fostering a strong connection. (6)
COLLABORATIONS AND PARTNERSHIPS:
Loop Media, Inc. has forged strategic collaborations and partnerships with renowned music labels: Universal Music Group, Sony Music, and Warner Music Group. These partnerships not only enrich Loop Media’s content library but also provide exclusive access to top-quality music videos and content from globally recognized artists. In addition, Loop Media has formed non-music content collaborations with industry leaders like Best of (AFV) America’s Funniest Home Videos, TikTok, US Weekly, GoPro, (WSL) World Surf League, Looney Tunes, Global Fashion Channel, and SportsNews Highlights. These partnerships further diversify Loop Media’s offerings and ensure a constant flow of fresh and engaging material for audiences. (6)
Loop Media, Inc. (AMEX: LPTV) is reshaping the digital entertainment landscape with its extensive content library and strategic collaborations. By offering an immersive and captivating experience, Loop Media captivates audiences and introduces them to a world of entertainment possibilities. The company’s commitment to curating engaging content, fostering discovery, and enabling personalized experiences positions it as a leader in the industry.
With music label partnerships, non-music content collaborations, and an ever-expanding content library, Loop Media, Inc. (NYSE American: LPTV) continues to redefine entertainment, unlocking new horizons for both viewers and content creators alike.
#4. SCALABILITY AND GROWTH: LOOP MEDIA, INC. (AMEX: LPTV) HAS DEMONSTRATED FINANCIAL AND OPERATIONAL MOMENTUM AS THE BUSINESS SCALES, ACHIEVING GROWTH ACROSS KEY METRICS AND INDICATING ITS POTENTIAL FOR FUTURE EXPANSION.(6)
Image Source (10)
LOOP MEDIA, INC. (AMEX: LPTV): BUILDING MOMENTUM FOR FUTURE EXPANSION
Loop Media, Inc. (AMEX: LPTV) is making significant strides in the digital entertainment industry, showcasing impressive scalability and growth potential. In this section, we explore the compelling trajectory of Loop Media as it continues to expand its operations and achieve key milestones. By examining the company’s financial and operational momentum, we gain valuable insights into its potentially promising future. (6)
DRIVING SCALABILITY:
Loop Media has strategically positioned itself for scalable growth within the digital entertainment landscape. By leveraging advanced technologies and innovative strategies, the company has laid a strong foundation for expanding its reach and market share.
Loop Media’s ability to effectively scale its operations positions it as a formidable player in the DOOH Media industry, capable of adapting to evolving market dynamics and capturing new opportunities.(6)
FINANCIAL AND OPERATIONAL MOMENTUM:
Loop Media’s success is evident through its financial and operational performance. The company has achieved significant milestones across key metrics, reflecting its consistent growth trajectory.
By carefully managing resources and executing efficient operational strategies, Loop Media has established a strong foothold in the market, paving the way for continued success. (6)
EXPANDING MARKET PRESENCE:
As Loop Media scales its business, it is also expanding its market presence. By strategically targeting key demographics and partnering with industry leaders, the company is poised for increased visibility and market penetration.
Loop Media’s ability to reach broader audiences through partnerships and collaborations unlocks new opportunities for revenue generation and establishes the company as a trusted entertainment provider. (6)
FUTURE EXPANSION PROSPECTS:
Loop Media’s impressive scalability and potential growth set the stage for exciting future expansion prospects. With a solid foundation in place and a clear vision for innovation, the company is well-positioned to capitalize on emerging opportunities in the digital entertainment industry.
Loop Media’s ability to adapt to changing consumer preferences and embrace technological advancements gives it a competitive edge and fuels anticipation for its continued growth and success. (6)
Loop Media, Inc. (AMEX: LPTV) has demonstrated remarkable scalability and growth potential for those looking for opportunities in the digital entertainment industry. With a strong foundation, coupled with a multi-faceted revenue model, Loop Media showcases its ability to navigate the evolving market landscape successfully.
As the company continues to expand its market presence and capitalize on emerging opportunities, the future looks bright for Loop Media, setting the stage for continued growth and success in the dynamic world of digital entertainment.(6)
#5. TECHNOLOGICAL FRAMEWORK: LOOP MEDIA’S PROPRIETARY TECH STACK SETS IT APART FROM COMPETITORS, ALLOWING FOR PRECISE AUDIENCE MEASUREMENT AND ENHANCING THE AD VIEWING EXPERIENCE. (6)
LOOP MEDIA, INC. (AMEX: LPTV): REVOLUTIONIZING DIGITAL ENTERTAINMENT THROUGH INNOVATIVE TECHNOLOGY
Loop Media, Inc. (AMEX: LPTV) has positioned itself as a leading player in the digital entertainment industry, driven by its commitment to innovative technology. In this section, we explore how Loop Media’s proprietary tech stack has revolutionized the industry, providing precise audience measurement and delivering an exceptional ad viewing experience.
By delving into the unique features and capabilities of Loop Media’s technology, we uncover the company’s competitive advantage and its potential for continued success. (6)
Image Source (16)
UNLEASHING THE POWER OF TECHNOLOGY:
Loop Media’s innovative technology stack has become the cornerstone of its success. This differentiated proprietary platform enables the company to offer unique and immersive digital entertainment experiences while delivering targeted and relevant content to its audiences. By harnessing the power of cutting-edge technology, Loop Media has set itself apart from its competitors, catering to the ever-evolving needs and preferences of today’s digital consumers. (6)
PRECISE AUDIENCE MEASUREMENT:
Image Source (7)
Loop Media’s technology stack incorporates advanced analytics tools that provide precise audience measurement. By leveraging data-driven insights, the company can gain a deeper understanding of its audience’s behavior, preferences, and engagement patterns.
This enables Loop Media to curate content that resonates with its viewers, ensuring a personalized and captivating entertainment experience. The ability to precisely measure audience metrics provides Loop Media with information to tailor its content offerings and provide advertisers with general information about the reach of Loop Media’s platform.(6)
ENHANCED VIEWING EXPERIENCE:
One of the standout features of Loop Media’s technology stack is its ability to enhance the content viewing experience. Loop Media’s technology not only benefits advertisers by reaching the right audience but also enhances the overall entertainment experience for viewers.(6)
INNOVATION AT THE CORE:
Innovation lies at the core of Loop Media’s technology stack. The company continually invests in research and development to stay at the forefront of digital entertainment trends.
By embracing emerging technologies and exploring new possibilities, Loop Media creates an environment of constant evolution and improvement. This commitment to innovation enables the company to adapt swiftly to changing market dynamics and deliver cutting-edge solutions. (6)
FUTURE GROWTH AND EXPANSION:
Loop Media’s innovative technology stack positions it for exciting future growth and expansion. With a solid foundation in place, the company is well-equipped to explore new markets and capitalize on emerging opportunities.
By staying ahead of the curve and leveraging its proprietary technology, Loop Media can continue to disrupt the digital entertainment landscape and solidify its position as an industry leader. (6)
Loop Media, Inc. (AMEX: LPTV) is at the forefront of digital entertainment, driven by its innovative technology stack. With precise audience measurement and an enhanced ad viewing experience, Loop Media sets new standards in the industry. Through continuous innovation and a commitment to delivering exceptional entertainment experiences, Loop Media is well-positioned for future growth and success.
If you’re looking for a dynamic company at the intersection of technology and entertainment, you should keep a close eye on Loop Media, Inc. (AMEX: LPTV) as it continues to revolutionize the digital entertainment landscape. (6)
#6. PRECISION IN TARGETED ADVERTISING: LOOP MEDIA’S PROPRIETARY TECH STACK ENABLES PRECISE AUDIENCE MEASUREMENT AND TARGETED AD PLACEMENT, MAXIMIZING THE EFFECTIVENESS OF ADVERTISING CAMPAIGNS.(6)
Image Source (18)
LOOP MEDIA, INC. (NYSE AMERICAN: LPTV): REVOLUTIONIZING ADVERTISING THROUGH TARGETED AUDIENCE ENGAGEMENT
Loop Media, Inc. (AMEX: LPTV) has emerged as a trailblazer in the digital entertainment industry, leveraging its proprietary tech stack to redefine the landscape of targeted advertising.
In this section of the report, we explore how Loop Media’s innovative technology enables precise audience measurement and delivers targeted ad placement, revolutionizing the effectiveness of advertising campaigns. By delving into the capabilities and advantages of Loop Media’s technology, we uncover the company’s unique position in driving successful advertising strategies.(6)
UNLOCKING THE POTENTIAL OF TARGETED AD PLACEMENT:
One of the standout features of Loop Media’s technology is its ability to deliver targeted ad placement. Through its sophisticated algorithms and robust ad-serving capabilities, Loop Media ensures that advertisements are strategically placed within relevant digital content.
Advertisers may set parameters as to, among other things, the type of venues in which they want their ads to play, the type of content against which they want their ads to play and the geographic area in which the ads are to be played. By providing advertisers with distribution choices, Loop Media can seek to maximize the impact of different advertising campaigns. This targeted approach enables advertisers to reach their desired audience more effectively, which should result in higher conversion rates and improved return on ad investment.(6)
ENHANCING THE ADVERTISING EXPERIENCE:
Loop Media’s technology not only optimizes ad placement but also enhances the overall advertising experience for viewers. By seamlessly integrating advertisements into the digital content, Loop Media ensures a mostly non-disruptive and engaging viewing experience.
Advertisements are seamlessly woven into the content, allowing for a natural and organic transition that captivates the audience. This approach not only elevates the user experience but also increases the likelihood of viewers engaging with the advertised content. (6)
DRIVING SUCCESSFUL ADVERTISING CAMPAIGNS:
With its targeted advertising capabilities, Loop Media drives successful advertising campaigns for its clients. By leveraging precise audience measurement numbers and strategic ad placement, Loop Media helps advertisers effectively reach their target audience with tailored messaging. The ability to connect brands with their ideal consumers in a meaningful and impactful way helps to ensure that advertising campaigns can yield positive results.
Loop Media’s technology equips advertisers with the tools they need to optimize their marketing strategies and drive desired outcomes. (6)
FUTURE OPPORTUNITIES FOR GROWTH:
Loop Media’s targeted advertising capabilities open doors to exciting future opportunities for growth. As the digital landscape continues to evolve, the demand for personalized and relevant advertising is on the rise.
With its innovative technology stack, Loop Media is well-positioned to capitalize on this trend and expand its reach in the advertising industry. By continually refining its technology and staying ahead of market trends, Loop Media is poised for continued success and growth. (6)
Loop Media, Inc. (AMEX: LPTV) is revolutionizing the advertising landscape with its targeted advertising capabilities. By leveraging its proprietary tech stack, Loop Media delivers strategic ad placement, driving successful advertising campaigns.
With an unwavering focus on audience engagement and personalized messaging, Loop Media empowers advertisers to connect with their target audience effectively.
Those looking for a company at the forefront of targeted advertising should closely follow Loop Media, Inc. (AMEX: LPTV) as it continues to redefine the effectiveness and impact of digital advertising strategies.(6)
#7. EXPERIENCED MANAGEMENT TEAM: THE COMPANY IS LED BY A SEASONED MANAGEMENT TEAM WITH EXTENSIVE EXPERIENCE IN LEADING MEDIA BRANDS, ENSURING STRONG LEADERSHIP AND STRATEGIC DECISION-MAKING. (6)
INTRODUCING LOOP MEDIA’S DYNAMIC MANAGEMENT TEAM: PIONEERS LEADING THE WAY TO SUCCESS (6)
Loop Media, a trailblazing multichannel streaming platform, owes its remarkable journey and innovative approach to the talented individuals who make up its management team. With their extensive experience and unwavering dedication, they have been instrumental in propelling Loop Media to new heights. Let’s meet the driving forces behind Loop Media’s success:
JON NIERMANN – CO-FOUNDER, CHIEF EXECUTIVE OFFICER
As the Co-Founder and Chief Executive Officer of Loop Media, Jon Niermann has been at the helm since May 2016. With over 30 years of media technology leadership under his belt, Jon’s visionary mindset has shaped Loop Media’s trajectory. His deep understanding of the industry, coupled with his strategic acumen, has been instrumental in driving the company’s growth and establishing its position as a leader in the streaming space.
NEIL WATANABE – CHIEF FINANCIAL OFFICER
Joining Loop Media in September 2021, Neil Watanabe brings with him a wealth of finance, accounting, and operational experience for both public and private companies. With over 30 years in the field, Neil’s expertise provides Loop Media with a strong financial foundation and strategic guidance. His meticulous approach to financial management ensures that Loop Media is well-positioned to seize new opportunities and drive sustainable growth.
BOB GRUTERS – CHIEF REVENUE OFFICER
Bob Gruters, the Chief Revenue Officer of Loop Media, joined the team in May 2021. Boasting a wealth of experience in key leadership positions within television, digital, print, and out-of-home media, Bob’s expertise in revenue generation and strategic partnerships has been invaluable. Under his guidance, Loop Media has expanded its revenue streams, driving business growth and establishing strong connections with industry stakeholders.
Liam McCallum, a Co-Founder of Loop Media, has been instrumental in shaping the company’s technological prowess. Joining the team in 2016, Liam brings over 20 years of coding and development experience to his roles as Chief Product Officer and Chief Technology Officer. His innovative thinking and technical expertise have been integral to the development of Loop Media’s cutting-edge streaming platform, ensuring a seamless user experience and staying ahead of the curve in an ever-evolving industry.
With such a dynamic and experienced management team at the helm, Loop Media, Inc. (AMEX: LPTV) is poised for continued success in the ever-evolving streaming landscape. Their visionary leadership, strategic expertise, and passion for innovation drive Loop Media’s commitment to delivering exceptional content and experiences to its audience. (6)
7REASONS WHY LOOP MEDIA, INC. (AMEX: LPTV) IS POISED FOR MEANINGFUL GROWTH IN 2023.
PRECISION IN TARGETED ADVERTISING:
Loop Media’s proprietary tech stack empowers the company with remarkable precision in audience measurement and the ability to place ads based on advertisers’ requests based on geographic location, the nature of content, and type of venue. By leveraging this technology, Loop Media seeks to maximize the effectiveness of advertising campaigns, ensuring the right message reaches the right audience. The company’s targeted advertising capabilities significantly enhance advertising outcomes and distinguish it from competitors. (6)
DISRUPTIVE MARKET OPPORTUNITY:
Loop Media, Inc. (AMEX: LPTV) operates in the digital out-of-home (DOOH) industry, which is experiencing strong growth and offers significant market potential. (6)
ENGAGING CONTENT LIBRARY:
Loop Media, Inc. (AMEX: LPTV) has a vast library of licensed and original content, providing a compelling and immersive entertainment experience for audiences. (6)
ANALYST COVERAGE:
B. Riley Securities Initiates Coverage on Loop Media, Inc. (NYSE American: LPTV) with a $5.00 Target. (19) According to Barchart.com, shares of (LPTV) opened at $1.97 on 8/7/2023 which could suggest over 153% in potential upside to the $5.00 target set by B. Riley Securities. (19)(1)
EXPERIENCED MANAGEMENT TEAM:
The company is led by a seasoned management team with extensive experience in leading media brands, ensuring strong leadership and strategic decision-making. (6)
TECHNOLOGICAL FRAMEWORK:
Loop Media’s tech stack allows for, among other things, accurate audience measurement, enhancing the viewing experience of advertisements. Loop Media’s commitment to utilizing cutting-edge technology sets it apart in the industry, providing a competitive edge. (6)
SCALABILITY AND GROWTH:
Loop Media, Inc. (AMEX: LPTV) has demonstrated financial and operational momentum as the business scales, achieving growth across key metrics and indicating its potential for future expansion. (6)
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, TD MEDIA LLC FOR A ONE DAY LPTV AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We are coming off a slew of recent double digit movers over the past two weeks.
I hope that you have been paying attention.
This next one has the potential to move based on two major catalysts…… The tiny float and the cash in the treasury alone. Factor in revenues starting and all of these could be major catalysts for this next one moving forward.
Turn your attention to SILO right away for Tuesday’s session.
Silo Pharma Inc (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Silo is committed to developing innovative solutions to address conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.
Intellectual property: To date, Silo has filed 4 provisional patent applications related to the use of the central nervous system-homing peptides covered by the UMB Option Agreement to deliver certain compounds, including a nonsteroidal anti-inflammatory drug and/or psilocybin, for the treatment of arthritis, central nervous system diseases, neuroinflammatory diseases as well as cancer. In addition, pursuant to the Company’s acquisition of NFID, Silo acquired three trademarks related to the NFID brand.
SILO IS HARNESSING THE POWER OF PSYCHEDELICS TO DELIVER BREAKTHROUGH MEDICAL SOLUTIONS
Silo has entered into research agreements and partnerships with multiple leading medical universities, including:
A sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease;
A scientific research agreement with the University of California San Francisco (UCSF) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation;
An exclusive license agreement with the University of Maryland, Baltimore (UMB) to explore a patent focused on enhanced targeting of therapeutic agents to the central nervous system;
A second exclusive option agreement with UMB to license a joint-homing peptide targeted at arthritis-inflamed joints; and
An agreement with Columbia University granting it an option to license two distinct assets currently under development, one focused on Alzheimer’s disease and a second focused on PTSD and stress.
Psilocybin is considered a serotonergic hallucinogen and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising, and Silo Pharma believes there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders. While classified as a Schedule I substance under the Controlled Substances Act (“CSA”), there is an accumulating body of evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug Administration (“FDA”) and U.S. Drug Enforcement Agency (“DEA”) have permitted the use of psilocybin in clinical studies for the treatment of a range of psychiatric conditions.
The potential of psilocybin therapy in mental health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated and has the potential to treat depression when administered with psychological support.
Silo Pharma has engaged in discussions with a number of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board that is intended to help advise management regarding potential acquisition and development of products.
In addition, as more fully described below, Silo Pharma has entered into a license agreement with the University of Baltimore, Maryland, and has entered into a joint venture with Zylo Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for targeted delivery of potential novel treatments. In addition, Silo Pharma has recently entered into a sponsored research agreement with Columbia University pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds.
Silo Pharma plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this new line of business.
SILO PHARMA SIGNS AGREEMENT TO DEVELOP FIRST-IN-CLASS KETAMINE IMPLANT THERAPEUTIC
INITIAL INDICATIONS ARE FIBROMYALGIA AND CHRONIC PAIN
ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
“Alongside our development of SP-26, our novel time-release topical formulation of ketamine, we are beginning to explore an additional option for treating fibromyalgia using ketamine-loaded implants,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The outcome of this research will provide additional information and data for our ongoing studies of ketamine treatments for fibromyalgia and other chronic pain indications.”
Fibromyalgia is a chronic condition causing widespread musculoskeletal pain accompanied by memory issues, sleep problems, and fatigue. The disorder affects about four million American adults, or about 2% of the adult population, and its treatment market is projected to grow at a compound annual growth rate of over 9% in the 2020-2027 period.1
SILO PIPELINE:
.Silo Pharma believes in following the science to identify the best application for a therapeutic rather by targeting indications with the biggest need and selecting the best route of delivery for patients. Our current assets have shown promise in a range of illnesses and diseases, including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.
SILO PHARMA’S PRIMARY ASSET HAS EXTRAORDINARY POTENTIAL
SPC-14 Targeting Alzheimer’s
505(b)(2) Pathway / preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University / SPC-14 has shown reduced hyponeophagia in animal studies / SPC-14 may reduce behavioral despair / Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab
Market Opportunity – Alzheimer’s Disease / 6.5 million Americans suffer from Alzheimer’s and related diseases / ~1 in 9 Americans 65+ have Alzheimer’s v U.S. market for relevant drugs expected to reach $5 billion by 2027
Technology – Licensed from Columbia University / SPC-14 is a novel drug combining two approved therapeutics / SPC-14 targets NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms in Alzheimers.
Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders / Increasing stress resilience in military, first responders, and other populations at high risk of PTSD / Predicting the level of severity or progression such disorders / Molecular targets for use in drug discovery of innovative treatments.
Market Opportunity – Targeted prophylactic treatment—Stress-induced affective disorders / 26% of Americans 18+ suffer from anxiety, PTSD and other disorders / This number has escalated post-COVID-19 / U.S. market for relevant drugs expected to reach $13 billion by 2027
Technology – Metabolomic biomarkers predict response to pharmacological treatments / Utilizes ketamine compositions as a method for treatment and prevention.
SP-26 Time-Released Psilocybin, Ketamine
Deliver Ketamine or Psilocybin in a time-released manner / Will time-release diminish the hallucinogenic effects of these psychedelics / Pre clinical study underway shows Z-pod can hold and distribute Ketamine / Efficacy study in animals underway.
Technology – Joint Venture with Zylö Therapeutics, Inc. / Clinical development of psilocybin using ZTI’s Z-pod technology / Clinical development of Zylo’s sustained release topical delivery system.
SPU-16 CNS Homing Peptide
May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord / May be used for diagnosing and monitoring MS / Decreases toxicity of existing therapeutics / Animal study results show much improved delivery of therapeutics and decreased toxicity.
Market Opportunity – Multiple Sclerosis (MS) / There are approximately 400,000 Americans and 2.5 million people worldwide with MS / The most widespread disabling neurological condition of young adults / Global market for MS drugs expected to reach $25.3 billion by 202
Technology- Licensed from University of Maryland Baltimore / Patent issued / Central nervous system-homing peptides / Use for investigation and treatment of MS and other neuroinflammatory pathology.
Identify markers of arthritic inflammation in joints / Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats / Peptide significantly inhibited arthritic progression in this animal model / Further studies are underway at UMB.
Market Opportunity – Rheumatoid Arthritis (RA) / 1.3M U.S. adults suffer from RA / The most common autoimmune disease in U.S. / U.S. market for RA drugs expected to reach $63 billion by 2027
Technology- Development plan to utilizing liposomal Homing Peptide to deliver targeted psilocybin / The ability of the peptides to target inflamed epithelium suggest they could be used to target drug delivery. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides can be used to treat autoimmune diseases, including but not limited to RA.
HOW SILO PHARMA’S DRUG DELIVERY PLATFORM COULD CAUSE MASSIVE CHANGES TO HOW DISEASES ARE TREATED
Research has clearly shown that psychedelics – such as psilocybin – can offer significant benefits to those suffering from a number of disorders. But to date, the issue has been developing a psychedelic-based solution for these sufferers that was both practical and effective. Thanks to the potential of SILO Pharma’s unique drug delivery platform – developed in conjunction with university research – we could be on the verge of a significant breakthrough in treatment. SILO Pharma’s assets and research could be transformative to the well-being of patients worldwide…and disruptive to the healthcare industry as a whole. That alone sets Silo Pharma (OTC: SILO) apart from others in both the psychedelic and biopharma arenas.
The research and development – based on the company’s unique homing peptide – could not only prove to be effective in the delivery of psychedelics…but also in delivery of traditional medication. That type of potential is deserving of attention from investors…but it’s also more difficult to project. A potential comparable stock that has demonstrated the potential for this company’s upside, however, does exist in the cannabis space.
1) Double Play Investment Opportunity – Unlike many companies generating attention in the psychedelic space, SILO Pharma is focused on developing potential breakthroughs by combining traditional therapeutics with the power of psychedelic research.
2) Rapidly Growing Market – The market for psychedelics is projected to grow at a CAGR of 16.3% between now and 2027, when it is expected to reach $6.8 billion.
3) Potential Game-Changing Drug Delivery Platform – SILO Pharma’s potentially game-changing drug delivery platform may be used to treat a number of devastating diseases, including Rheumatoid Arthritis and Multiple Sclerosis and is likely to generate considerable attention from larger companies, making for attractive buyout potential.
4) Following a Proven Blueprint for Success – The company is following the same path forged in the cannabis sector by GW Pharma, and is working to combine the powerful healing benefits of psilocybin with its own unique drug delivery system in the hopes of developing a true game-changer that could ultimately prove disruptive to the entire healthcare industry.
5) Proven Leadership Team – Silo Pharma is led by an experienced team of business builders and researchers poised to make the company’s dream a reality. This team includes CEO Eric Weisblum, with over 20 years investing, building and managing businesses as well as an impressive scientific advisory board.
SILO PHARMA’S IS LED BY AN EXPERIENCED MANAGEMENT TEAM AND AN IMPRESSIVE GROUP OF SCIENTIFIC ADVISORS
CEO Eric Weisblum has over 20 years investing, building and managing businesses and will lead a scientific advisory board of reputable medical professionals to work and guide the company through the different stages of research, licensing, partnerships and trials.
Prior, Mr. Weisblum was President of Sableridge Capital for five years. Eric currently serves on the board of directors of Aikido Pharma., a Nasdaq listed biotech company focused on the commercialization of oncology therapeutics. In addition to being an active investor in both public and private companies, Mr. Weisblum has provided managerial assistance and guidance to help companies execute on their business strategy.
Director Wayne Linsley has been an entrepreneur for over 40 years. In 1979, he received a Bachelor’s Degree in Business Administration from Sienna College in Loudonville, New York.
He has since been involved with real estate brokerage and residential development, construction, finance, telecommunications. Since 2009 he has worked for and is currently a Vice President for CFO Oncall, Inc., a financial reporting firm that works with publicly traded companies.
Director Kevin Munoz, MD, currently serves as Director of Operations at Physical Medicine and Rehabilitation where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY SILO AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We have one last profile for you to watch as we head into the weekend. It certainly has been a busy week for us here but we were able to watch some significant movers in the market.
We have another profile that we have never before profiled on this newsletter before.
Pull up OKYO Immediately.
Take a look at the chart below. This one bounced off of the 52 week lows and has been moving up on light interest which is a very bullish sign for this one.
OKYO Pharma Limited is a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain. The Company’s lead candidate to treat dry eye disease, OK-101, is currently in Phase II clinical trials in the US.
A range of ocular diseases, like glaucoma, uveitis and retinal diseases are most prevalent in the geriatric population, and rates of disease are increasing as the population ages. One of the most common ocular diseases is dry eye disease (DED). It affects almost 50 million people in the US, and the global market for DED was worth $4.5 billion in 2022. It is predicted to reach $6.3 billion by 2028, at a compound annual growth rate (CAGR) of 5.67% during the forecast period.
OKYO Pharma Ltd. (NASDAQ: OKYO) is a biopharma leading the way when it comes to developing novel treatments for DED and ocular pain. Founded in 2018, the company was able to bypass phase 1 safety trials and has begun screening patients for its phase 2 efficacy trials.
The trial includes 240 patients, and OKYO anticipates having topline data on its drug, OK-101, in Quarter 4 of 2023. OK-101 uses a novel chemerin receptor that both acts as an anti-inflammatory agent and reduces corneal neuropathic pain in the patient. As the treatment is administered topically as eye drops, there is almost no risk of systemic exposure or risk of the treatment getting into the bloodstream.
If the trial meets its pre-specified endpoints, this could contribute data toward registration trials, and speed up OK-101’s timeline for approval from the Food and Drug Administration (FDA).
The company is laser-focused on bringing its treatment to market, as it believes the treatment has significant potential in the sector. With recent acquisitions indicating a commitment from big biopharmaceuticals to the ophthalmology market, there may be many eyes watching the progress of OKYO’s phase 2 trials.
In 2018, OKYO successfully obtained (via assignment from Panetta Partners Limited, a related party) an exclusive license from On Target Therapeutics (OTTx) to patents owned or controlled by OTTx and a sub-license from OTTx to certain patents licensed by OTTx from Tufts Medical Center (TMC) to support its ophthalmic disease drug programs. These licenses gave OKYO the right to exploit the IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation such as DED with lipid-linked chemerin analogues. OKYO also has a license from TMC to a separate IP estate for treating symptoms of ocular neuropathic pain, uveitis and associated pain. The scope of the TMC IP granted use through the sublicense with OTT is commensurate with the scope of use of the IP granted to OTT from TMC. This intellectual property, which includes 3 patents related to OK-101 including technology, dry eye, and neuropathic pain, forms the basis of OKYO’s OK-101 program.
CHEMERIN RECEPTOR
Chemerin, the endogenous agonist of chemerin receptor ChemR23, a specific member of the G protein coupled receptor (GPCR) class, activates immune cells at the inflammation site.
Chemerin activates ChemR23 on circulating monocytes and macrophages, recruiting these cells to the inflammation site.
Chemerin is also physiologically cleaved into smaller potent anti-inflammatory peptides that reprogram macrophages to repress inflammation inducing anti-inflammatory cytokines at the inflammatory site, thus restoring normal tissue structure and function.
OK-101, OKYO’s lead drug candidate contains a stable chemerin-derived 10-mer peptide as the active anti-inflammatory component of the drug, along with a conjugated lipid component, producing both enhanced agonist potency along with wash resistance.
OK-101 DRUG CANDIDATE
One of the major challenges with topical administration of any drug designed for treating OED is drug wash-out through natural processes of tearing and blinking, minimizing drug ‘residence’ time at the ocular site needed to provide a pharmacologic benefit.
Membrane Anchored Peptide (MAP) technology enabled the development of a long acting and stable OK-101 drug candidate.
OKYO’s lead drug candidate OK-101 consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain.
Unique MAP technology enabled the development of a drug with enhanced potency and the expectation of increased drug residence time on the ocular surface.
DRY EYE DISEASE
Approximately 5 million people suffer from ocular pain every year.
Neuropathic corneal pain, a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available.
Current treatments are limited to short term NSAIDs, steroids, and opioids in severe cases. Side effects and the risk of addiction to opioids is a serious concern.
The Global ocular pain market is expected to reach $0.5 Billion by 2030.
Topical administration of OKYO’s lead drug candidate OK-101 was effective in suppressing corneal pain in a ciliary nerve ligation mouse model of neuropathic corneal pain; exhibiting a potency similar to that of gabapentin, a commonly used oral drug for neuropathic pain that was conversely given by intraperitoneal injection.
The pain-relieving potential of a dry eye drug would provide an important benefit to the considerable number of dry eye patients suffering from ocular pain in addition to the existing inflammatory effects of the condition.
ALLERGIC CONJUNCTIVITIS
Allergic conjunctivitis, often called ‘pink eye’ is an inflammation of conjunctiva, caused by an allergic reaction to pollen, mold, smoke, dust etc.
Up to 40% of the global population suffers from allergic conjunctivitis, which is mostly treated with antihistamines and corticosteroids (2018 annual revenue in US was > $1 Billion). Notably, a significant number of patients do not respond to antihistamines which typically leads to overuse of corticosteroids in these patients.
In an animal model, OKYO’s lead drug candidate OK-101 was effective in suppressing ocular inflammation by downregulating key inflammatory CD4+ T cells.
Uveitis is the third leading cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can damage vital eye tissue, leading to permanent vision loss.
Uveitis is currently treated with corticosteroid eyedrops and injections that reduce inflammation, (2018 annual revenue in US was > $500M). However, the long-term use of corticosteroids causes risk of cataract and glaucoma, requiring close monitoring for their potential side effects.
In an animal model, our lead drug candidate OK-101 was effective in suppressing ocular inflammation by downregulating key inflammatory biomarkers CD4+ T cells.
Our focus is to suppress the inflammation and pain associated with the uveitis using our lead drug candidate OK-101.
OCULAR PAIN
Worldwide, ~700 million patients suffer from dry eye disease. In US, ~30 million patients suffer from dry eye disease.
Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected.
Prevalence of dry eye is expected to increase substantially due to an aging population and increased use of contact lenses and digital screen time.
Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease.
Dr. Jacob has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. Dr. Jacob is the Co-Founder and former CEO and Chairman of Synergy Pharmaceuticals. During his time at Synergy, he served as Chairman, Chief Executive Officer and Executive Chairman, and is the co-inventor of Synergy’s FDA-approved drug Trulance® which is currently marketed in the U.S. by Bausch Health, Inc. to treat functional GI disorders. Dr. Jacob is also the former CEO and Managing Director of Immuron Inc., an Australian biotechnology company dual-listed on the Australian ASX exchange and on NASDAQ. Dr. Jacob currently is Chairman of the Board of Hepion Pharmaceuticals, Inc., a public NASDAQ listed company with a drug in clinical development to treat nonalcoholic steatohepatitis (NASH), and is also on the Board of Directors of Cardiff Oncology, Inc., a NASDAQ listed public oncology company. He served as Chief Executive Officer and Director of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013.
Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he was Director of Glycobiology and a Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. Dr. Jacob holds over 30 patents and is the co-inventor of two pharmaceutical drugs which are FDA approved. Dr. Jacob earned a B.S. cum laude in Chemistry from the University of Missouri, St. Louis and holds a Ph.D. in Biochemistry from the University of Wisconsin, Madison.
RAJ PATIL, PHD
CHIEF SCIENTIFIC OFFICER
Dr. Patil brings 30 years of ophthalmic experience and a powerful combination of academic scholarship and pharmaceutical R&D excellence.
Raj previously worked with Ora Inc, as Vice President of Research & Development, where he was responsible for driving all anterior and posterior segment research of Ora’s R&D Institute. Earlier in his career, he worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. His tenure at iVeena included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School and Principal Investigator at Singapore Eye Research Institute.
Raj also held a number of leadership roles at Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology glaucoma and retina research. Prior to joining the business world, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology & Genetics at University of Nebraska Medical Centre in Omaha and as an Assistant Professor of Ophthalmology, Molecular Biology & Pharmacology at Washington University in St. Louis.
Raj received his PhD in Biochemistry from National Chemical Laboratory/University of Pune, India and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor, MI. He is the recipient of Olga Keith Wiess Special Scholar Award from Research to Prevent Blindness Foundation and NIH Director’s New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles and serves as reviewer and editorial board member for numerous journals and is frequently invited to lecture at academic and industry events.
KEEREN SHAH
CHIEF FINANCIAL OFFICER
Keeren Shah serves as our Chief Financial Officer. Ms. Shah currently also serves as the Finance Director of Tiziana Life Sciences LTD, Accustem Sciences Limited and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining the Company, Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as well as leading and participating in key transformation programmes and Visa Inc.’s initial public offering. Before joining Visa, Ms. Shah also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of Arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.
Willy Simon, Non-Executive Director
Willy Jules Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences plc.
John Brancaccio, Non-Executive Director
Mr. Brancaccio, a retired CPA, is a financial executive with extensive international and domestic experience in pharmaceutical and biotechnology for privately and publicly held companies. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio is currently a director of Cardiff Oncology, Inc., Hepion Pharmaceuticals, Inc., Rasna Therapeutics, Inc., and Tiziana Life Sciences plc.
Bernard Denoyer, Non-Executive Director
Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc, from July 2008 until FDA approval and his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc. From October 2000 to December 2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc. Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a master’s Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honours from Columbia Business School in 1972 and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He is currently serving on the Board of Trustees for two not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc.
SCIENTIFIC ADVISORY BOARD
Napoleone Ferrara, MD, Board Member
Dr. Ferrara is a Professor at the University of California San Diego Medical Center and a member of The National Academy of Sciences and has received numerous prestigious awards, including the Lasker Award and the Breakthrough Prize in Life Sciences. His research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the discovery that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis®), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Ranibizumab and other anti-VEGF agents have had a dramatic impact on the development of therapies for these blinding disorders. When Lucentis® (Ranibizumab) received FDA approval in late June 2006, the new macular degeneration drug was celebrated as a major medical breakthrough. Dr. Ferrara’s research also led to the development and approval of humanized anti-VEGF mAbs (Bevacizumab; Avastin®) for cancer treatment, with Avastin® being one of the bestselling cancer drugs over the last two decades. Lucentis® and Avastin® collectively achieved over $9 billion in sales last year.
Pedram Hamrah, MD, FRCS, FARVO, Board Member
Pedram Hamrah, MD is Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at New England Eye Center at Tufts Medical Center in Boston. Dr Hamrah’s research interests focus on corneal immunology and neuroscience, ocular imaging (immuno-imaging), ocular surface diseases and corneal neuropathic pain. He is currently on faculty at the departments of Ophthalmology and Bioengineering at Tufts University, where he is the director of clinical research and director of the Center for Translational Ocular Immunology. In addition, he is a faculty member at the immunology, neuroscience, and cell, molecular and developmental biology graduate programs at the Sackler School of Graduate Biomedical Sciences at Tufts. Throughout his career, he has focused on discovery, patient care and teaching. Dr. Hamrah currently serves on over a dozen editorial boards, is the associate editor for The Ocular Surface and TVST, section editor for Eye and assistant editor at Ocular Immunology and Inflammation.
Jay S. Pepose, MD, PhD, FARVO
Dr. Pepose, a specialist in refractive surgery and corneal and external diseases, is the founder and Medical Director of the Pepose Vision Institute and held the Bernard Becker Chair in Ophthalmology and Visual Sciences at Washington University School of Medicine in St. Louis. He is a consultant to numerous ophthalmic drug and device companies and serves as a Director and Chief Medical Advisor for Ocuphire Pharma. Dr. Pepose has been involved in over 40 clinical research trials, including registration trials for dry eye drugs, and has been the recipient of R-01 grant support from the National Eye Institute. He has served on the editorial boards of numerous prestigious journals, including the American Journal of Ophthalmology, Investigative Ophthalmology & Visual Science (IOVS), Cornea, and The Journal of Refractive Surgery and has over 200 peer reviewed publications. Dr. Pepose, an ARVO Gold Fellow, is a recipient of the Cogan Award from the Association for Research in Vision and Ophthalmology (ARVO) and the Life Achievement Honor Award from the American Academy of Ophthalmology. Dr. Pepose received an A.B. and M.A. in neurophysiology from Brandeis University and completed the M.D.-Ph.D. program at UCLA School of Medicine. He completed ophthalmology residency at the Wilmer Institute at the Johns Hopkins Medical Center and fellowship training at Georgetown University Medical Center
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY A THIRD PARTY, LEGENDS MEDIA LLC FOR A ONE DAY OKYO AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
CASH AND CASH EQUIVALENTS WERE $5.3 MILLION AS OF MARCH 31, 2023
30+ BRANDS HAVE DESIGNED WISA TECHNOLOGIES INTO THEIR PRODUCTS
AS ANNOUNCED ON MAY 15, 2023, THE COMPANY EXPECTS ITS PLANNED ACQUISITION OF COMHEAR TO CLOSE IN THE THIRD QUARTER OF 2023 AND BE ACCRETIVE IN THE FOURTH QUARTER OF 2023. AS A RESULT, THE COMPANY IS GUIDING FOR FULL YEAR 2024 REVENUE IN THE RANGE OF $10 MILLION TO $15 MILLION
— WiSA Technologies (@AssociationWisa) May 17, 2023
_______________________________
Hello Everyone,
We have another company to you to research for Thursday’s session.
This is a company that we have never profiled on this newsletter before.
Pull up WISA immediately.
WiSA Technologies (Nasdaq: WISA) develops, markets, and sells spatial audio wireless technology for smart devices and next-generation home entertainment systems. Its consortium—the WiSA Association—works with leading consumer electronics companies, technology providers, retailers, and industry partners to make spatial audio an experience that everyone can enjoy. The Company is headquartered in Beaverton, OR.
This one has some incredible catalysts driving it right now.
Strong IP position and significant patent coverage for immersive audio, with highly- differentiated multichannel wireless audio technology and existing implementations in premium audio brands
World-class premium technology ported to low-cost IoT chips to address mass market audio systems with software roadmap to address TAM of over 2 billion units
Establishment and management of the Wireless Speaker and Audio Association with interoperability specification, testing, and compliance standard
30+ brands have designed WiSA technologies into their products, with expanded opportunities from Comhear’s products and target markets
Strong revenue growth from combined company for modules sales, audio systems sales, and licensing
Another MAJOR catalyst is the recent letter of intent signed by the company:
WISA TECHNOLOGIES SIGNS LETTER OF INTENT TO ACQUIRE COMHEAR, INC.
– Transaction expected to be accretive beginning in Q4 2023 –
– Complementary technology and solutions in immersive wireless audio –
BEAVERTON, Ore.–(BUSINESS WIRE)– WiSA Technologies, Inc. (Nasdaq: WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, has signed a non-binding letter of intent to acquire Comhear, Inc. (Comhear), a developer of AI-enabled adaptive audio technology. The transaction is expected to close in the third quarter of 2023 and be accretive in the fourth quarter of 2023.
Comhear’s proprietary adaptive filtering and beam steering system captures environmental room dynamics, processes data in real-time, and adjusts the audio output. The result is dynamic immersive audio that delivers personalized audio experiences in multiple applications, including home entertainment, gaming, retailing, and location-based entertainment.
“The synergy between the two companies is compelling on many levels, with similar business models driven by audio IP, licensing and module sales,” said Brett Moyer, CEO of WiSA. “We are targeting many of the same customers yet offer complementary solutions that address different use cases, providing WiSA’s sales team with more products to sell to our customers. We are both poised to penetrate the audio market through licensing our technologies. The acquisition of Comhear enhances WiSA’s position as a leader in immersive wireless audio technology, and we expect that the combined company will be well positioned to take market share in this growing market.”
“We expect the addition of Comhear to be accretive beginning in Q4 2023. As a result, we are guiding for full year 2024 revenue in the range of $10 million to $15 million,” added Moyer.
“With the shared vision to deliver next generation immersive audio, I am thrilled to join forces with WiSA and look forward to assuming the role of Chairman of the combined companies following the acquisition,” said Andy Arno, Chairman of Comhear. “Our strategy to license and sell IP-embedded audio modules perfectly overlaps with WiSA’s business model, and our technology is a natural fit in WiSA’s ecosystem. The combined company can leverage WiSA’s many established customer relationships with new products along with additional market segments that have been the focus of Comhear.”
Terms of the Proposed Transaction
Under the proposed acquisition, WiSA would acquire all shares of Comhear common stock in exchange for newly issued shares of WiSA common stock.
The board of directors of the combined company is expected to consist of seven members, four of whom will be appointed by WiSA, including Mr. Moyer, and three of whom will be appointed by Comhear, including Mr. Arno as chairman.
The letter of intent for the proposed transaction is non-binding, and the parties expect to enter into one or more definitive agreements with respect thereto in June 2023. Completion of the transaction is subject to, among other matters, the completion of due diligence, the negotiation of definitive agreements providing for the proposed transaction, and satisfaction of various conditions to be negotiated therein and customary for transactions of the type contemplated, including, but not limited to, receipt of regulatory approvals, the provision of an audit of Comhear’s financial statements, and board of director and WiSA shareholder approvals.
The company expects to issue a proxy statement seeking shareholder approval for the proposed transaction in July 2023. However, there can be no assurance that the parties will successfully negotiate and enter into definitive agreements regarding the proposed transaction, or that the proposed transaction will be completed as currently contemplated, or at all.
About Andrew Arno
Andrew Arno has over 30 years of experience handling a wide range of corporate and financial matters, including work as an investment banker and strategic advisor to emerging growth companies. Mr. Arno served as Chairman of C.E. Unterberg, Towbin, an investment bank, and currently serves on the boards of directors of Smith Micro Software, Inc. and Independa Inc., both software companies, Oncocyte Inc., a medical diagnostics company, as well as Comhear, Inc. Mr. Arno received a BS degree from George Washington University.
WISA TECHNOLOGY PRODUCTS ENABLE THE WORLD’S BEST BRANDS TO TRANSMIT AND RECEIVE ULTRA HIGH-QUALITY AUDIO—WIRELESSLY.
Superb quality, simple setup, and perfect synchronization are all traits that embody WiSA technology. And the brands that incorporate our technology into their products would settle for nothing less. Whether you’re developing TVs and sound systems or purchasing them for your home or business, WiSA ensures your wireless entertainment experience exceeds all expectations.
WISA LAUNCHES TWO NEW POWERFUL TOOLS FOR IMPLEMENTING, MANAGING AND TESTING WISA-ENABLED PRODUCTS
Tools provide customers with comprehensive support for developing and manufacturing WiSA E and WiSA DS designs for multichannel audio
BEAVERTON, Ore.–(BUSINESS WIRE)– WiSA Technologies, Inc. (NASDAQ: WISA), a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems, announces two new tools available to WiSA Technologies’ customers designed to streamline the development and manufacturing of WiSA E and WiSA DS implementations. The new WiSA Server, in combination with the new Product Support Engineering Tool (PEST), enables faster time-to-market as well as comprehensive management of testing and other aspects of the manufacturing process.
The WiSA Server and PEST tools join the latest version of the mobile app, launched in December 2022, as the latest software-based applications designed to support the WiSA ecosystem of users, product designers and manufacturers.
WiSA Server
Running on the product application processor, WiSA Serveris a low-overhead software package that minimizes the time and effort required by customers to design systems using WiSA software. The WiSA Server Software Design Kit (SDK) provides high-level WiSA API commands via the product and mobile client interfaces and translates them into low-level I2C commands eliminating months from typical development cycles. Benefits include:
Accelerates product integration with simple, design-proven and tested API commands that significantly reduce code complexity and development time.
Ensures correct by-design interoperability across product families.
Supports Linux or RTOS operating system environments.
Automatically manages system push/pull notifications to all connected client devices. (e.g., volume notifications between mobile device, soundbar and speaker).
Product Support Engineering Tool (PEST)
In addition to managing and simplifying manufacturing module testing and programming, PEST provides efficiencies in test and manufacturing to make products operational and production ready. Benefits include:
Software programming support to update WiSA modules.
Tracking and traceability for product modules and final products.
Configuration support for WiSA modules, including device types, speaker locations, country code and manufacturing data.
Production test support for WiSA modules and final products including IOs, power, RF/Wi-Fi, audio, and pairing.
“We are doing everything possible to help our customers streamline their upfront development efforts and manage their manufacturing and testing of WiSA E and DS modules,” said Tony Parker, vice president of business development and strategy at WiSA Technologies. “The WiSA server dramatically helps customers reduce upfront development efforts, while the PEST tool provides powerful tracking and management of the final production process. Both add tremendous value to our customers as they develop and manufacture enabled products.”
For customers designing products with WiSA E or DS modules, WiSA Technologies offers a software design kit (SDK) for the WiSA Server and a manufacturing design kit (MDK) for the PEST tool. For more information about the WiSA Server and PEST tools.
Brett Moyer is a founding member of the Company and has served as the President and Chief Executive Officer of the Company and as a member of its board of directors since August 2010. From August 2002 to July 2010, Mr. Moyer served as president and chief executive officer of Focus Enhancements, Inc., a developer and marketer of proprietary video technology. From February 1986 to May 1997, Mr. Moyer worked at Zenith Electronics Inc. a consumer electronic company, where he had most recently been the vice president and general manager of its Commercial Products Division. Since June 2016, Mr. Moyer has also served as a member of the board of directors of Alliant International University, a private university offering graduate study in psychology, education, business management, law and forensic studies, and bachelor’s degree programs in several fields. From 2003 to December 2015, he served on the board of directors of HotChalk, Inc., a developer of software for the educational market, and from March 2007 to September 2008, he was a member of the board of directors of NeoMagic Corporation, a developer of semiconductor chips and software that enable multimedia applications for handheld devices. Mr. Moyer received a Bachelor of Arts in Economics from Beloit College in Wisconsin and a Master’s of Business Administration with a concentration in finance and accounting from Thunderbird School of Global Management.
GEORGE OLIVA
Senior Vice President of Finance and Strategic Operations of the Company
George Oliva joined WiSA Technologies, Inc. in 2019 as the Chief Financial Officer. Mr. Oliva has over 25 years as a senior finance professional, with a background in corporate finance, treasury, financial planning and analysis, manufacturing cost, international tax, and strategic planning. Most recently, he was a partner with Hardesty LLC, a national executive services firm. Mr. Oliva has held several CFO positions. At Penguin Computing, he orchestrated a turn-around. At StorCard, he guided the early-stage company in capital financing and more. At StreamLogic, a public company doing business as Hammer Storage Solutions, he navigated its going-private transaction. Prior to serving in such roles, Mr. Oliva was responsible for financial planning and analysis and operational support as the operations controller for Conner Peripherals and Read-Rite Corporation. Mr. Oliva began his career in auditing with Arthur Andersen & Co. He earned a degree in Business Administration from U.C. Berkeley with a dual emphasis in Accounting and Finance.
GARY WILLIAMS
Chief Accounting Officer and Vice President of Finance
Gary Williams has served as Chief Accounting Officer since September 9, 2019 and as Vice President of Finance since the Company’s founding in August 2010. Mr. Williams previously served as Secretary and Chief Financial Officer since the Company’s founding in August 2010 until September 9, 2019. In addition, Mr. Williams served as the Chief Financial Officer of Quantum3D, Inc., a training and simulation technology company, from November 2012 to September 2016. Prior to joining the Company, Mr. Williams served as secretary, vice president of finance and chief financial officer of Focus Enhancements Inc., a developer and marketer of proprietary video technology, from January 2001 to July 2010, when the videography and semiconductor businesses of the company were purchased by VITEC Multimedia, Inc. and the Company, respectively. Mr. Williams served as controller, vice president of finance, chief financial officer and secretary of Videonics Inc., a publicly traded company in the consumer electronics business, from February 1995 to January 2001, when Videonics merged with Focus Enhancements, Inc. From July 1994 to January 1995, Mr. Williams served as controller for Western Micro Technology, a publicly traded company in the electronics distribution business. From January 1990 to June 1994, Mr. Williams worked in public accounting for Coopers & Lybrand LLP. Mr. Williams is a certified public accountant, inactive, and received a Bachelor’s Degree in Business Administration, with an emphasis in Accounting, from San Diego State University.
ED GREEN
Vice President of Operations
Ed Green is a founding member of WiSA Technologies, Inc. serving as Vice President of Operations. Currently reporting to Mr. Green are the Production & Test Engineering, Quality and Reliability, and the IT departments. Prior to joining WiSA Technologies, Inc., Mr. Green held several positions at Network Elements Inc., Beaverton, OR. Most recently, Mr. Green was Product Line Manager for NEI’s 10 Gigabit Ethernet group. Mr. Green was the driving force behind NEI’s XENPAK, X2 and XFP programs. Over Mr. Green’s four year career at NEI, he was responsible for all design-for-test (DFT) on NEI’s 10Gb/s SERDES IC, and validation of NEI’s first multi-protocol ASIC. In 2000, Mr. Green served as Chief Operating Officer for Sunhoo.com based in Shanghai, China. There, Mr. Green was responsible for the development and implementation of the company’s business model and plan for a financial web portal in China. For the seven years prior to Sunhoo.com, Mr. Green operated a small chain of family entertainment centers. Mr. Green was responsible for all design, construction, implementation, management, and financial and corporate matters involving the company’s five stores and 70 employees. Mr. Green earned his BS in Electrical Engineering in 1983, and his MBA in Accounting in 2004.
JAMES CHENG
Vice President of Worldwide Sales
Cheng has more than 15 years of experience leading international business development for Silicon Valley tech brands with extensive experience in ecosystem and partner development. Prior to joining WiSA Technologies, Inc., he was VP marketing and business development at Amlogic, Inc., a global fabless SoC company that provides open platform solutions for multimedia consumer devices. Prior, Cheng was director of strategic accounts at GoerTeck, Inc. and senior director of business development at Marvell Semiconductor where he was responsible for developing Google 1st party brand and ecosystem partner business. He holds a B.E. degree in electrical engineering from Tamkang University, a PhD in electrical engineering from Stony Brook University and an MBA from NYU Stern School of Business.
KEITH GREENEY
Vice President of Engineering
Keith Greeney is a founding member of WiSA Technologies, Inc. serving as Vice President of Engineering. Mr. Greeney manages five groups within WiSA Technologies, Inc.; Research and Development, System Testing, FW Development, Application Development, and Reference Design Development. Mr. Greeney has over 25 years of experience in Firmware, Hardware, Digital Signal Processing (DSP) and ASIC design. He began his career as a system configuration manager at Applied Research Laboratories while pursuing a BSEE from the University of Texas at Austin. Prior to joining WiSA Technologies, Inc., Mr. Greeney was a key contributor to Tektronix’ Federal Systems, the group responsible for developing the world’s first real-time digital spectrum analyzer, the Tektronix 3052. Along with algorithm design and design-for-test (DFT) responsibilities for the 3052, Mr. Greeney developed and implemented the production line. At WiSA Technologies, Inc., he is responsible for the successful design and implementation of over 10 ASICs ranging from scan converters, alpha blenders, UWB and Wireless Audio for key customers including Bang & Olufsen, Intel, and Microsoft Xbox.
TONY OSTROM
President WiSA
Tony Ostrom is the President of the Wireless Audio and Speaker Association (WiSA). His 25-year career in the consumer electronics industry has been focused on product planning and development, consumer research, technology integration, go-to-market planning, marketing, training and sales. Prior to joining WiSA Tony was the Vice President of Product Development at Klipsch Group where he managed multiple categories including Wireless Home Theater, Wireless Distributed Audio, Bluetooth and Powered Audio Solutions. Prior to Klipsch, Tony played key roles in the global launches of Powermat Wireless Charging as well as the House of Marley audio and lifestyle brand. Tony was Director of Product Development and Marketing at Klipsch Group where he drove the Mass Retail and Personal Audio categories and started his career at JL Audio where he was a Technical Director. Tony has a BA in Music Engineering and a Minor in Physics from Ball State University, Muncie Indiana.
TONY PARKER
Vice President of Business Development and Strategy
Tony Parker is a founding member of WiSA Technologies, Inc. serving as Vice President of Business Development and Strategy. Mr. Parker has 25 years of experience in semiconductor marketing leadership, with extensive expertise in wireless markets, including WiFi and UWB. Prior to joining WiSA Technologies, Inc., he was director of marketing with Cirrus Logic for ARM system-on-chip solutions and audio DSP products for decoding and post processing of sound effects targeting AVR, DTV and automotive applications. Prior to that, he was senior manager of corporate strategy and technology for Agere Systems, directing and leveraging company-wide resources across multiple product families including data networking, mobile, and storage businesses. Parker also has a proven track record of developing and delivering the right products to semiconductor markets while working in key product management and marketing management positions at Texas Instruments, AT&T, and Lucent Technologies. Mr. Parker holds a BS degree in Electrical Engineering from Bradley University, Peoria Illinois, as well as an MBA degree from Syracuse University, Syracuse, NY.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, SICA MEDIA LLC FOR A ONE DAY WISA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We have another profile with several catalysts in play that we want you to take a look at for Monday’s session.
We are seeing activity starting to really pick up on this one.
Pull up BCAN immediately.
In the adult toy industry, AI and wearable sex toys have the potential to revolutionize the market, which is expected to be worth $62.32 billion by 2030. (9)
One company to keep an eye on in this space in the AI-power sex toy market is BYND Cannasoft Enterprises Inc. (BCAN).
This one has a few catalysts to look at:
HIGHER POTENTIAL FOR GROWTH:
In general, micro-cap companies have market capitalizations of between $50 million and $300 million. (17) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly. (17) As of 7/19/23, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has a market cap of approximately $51.49M according to MarketWatch.com. (18)
EXTREMELY LOW FLOAT:
Stocks with low floats have the potential to present significant swings. (4) BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has less than 9M shares available in its public float according to MarketWatch.com. (19)
HUGE MARKET:
The global sensual wellness market is projected to be worth $125B by 2026 with the intimate technology market expected to reach $62.32B by 2030, presenting a significant opportunity for a company like BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) to capture a portion of this market with its AI-powered adult toy technology. (2) (1)
Positive news on patent applications for BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) could prove to be a significant catalyst in 2023. The company’s recently filed a PCT application for their EZ-G device, which uses AI and sensors to provide a more sensual experience. (1) If positive news on the patent application comes out, it could lead to increased confidence and significant upside potential.
As an early mover in the AI-powered adult toy market, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) has the potential to establish itself as a leading player in the industry, providing a competitive edge over later entrants. (1)
High insider ownership typically signals confidence in a company’s prospects and ownership in its shares. (6)BYND Cannasoft Enterprises Inc. (BCAN) insiders own approximately 64.09% of the shares as of 7/19/2023 according to Finviz.com. (5)
_____
As of 7/19/23, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has less than 9M shares available in its public float according to MarketWatch.com. (19)
Not to mention, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) could have a higher potential for growth given their status in the market as a micro-cap.
In general, micro-cap companies have market capitalizations of between $50 million and $300 million. (17) Because micro-cap stocks are significantly smaller than mid-cap or large-cap companies, they have a higher potential to change valuation quickly.(17)
As of 7/19/23, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has a market cap of approximately $51.49M according to MarketWatch.com. (18)
Overall, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) has several positive catalysts, such as its potential for growth and low public float, making it an attractive option for those looking to take advantage of swings with significant potential.
Maybe that’s why BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) insiders are holding onto so many shares according to Finviz. (5)
Strong insider ownership can be an indication of a company’s health and long-term potential. When insiders own a significant percentage of a company’s shares, they have a vested interest in the company’s success, which can align their interests with those of other shareholders.
High insider ownership typically signals that insiders believe in the company’s future prospects and have confidence in its management team.
BYND Cannasoft Enterprises Inc. (BCAN) has over 64% insider ownership, (5)mv which is a strong indication of confidence in the company’s future prospects.
This level of insider ownership could be a sign that the management team has a significant stake in the company’s success. When insiders own a large percentage of a company’s shares, it can also indicate that they are committed to the company for the long term, as they have a significant financial stake in its future performance.
The market often views high insider ownership as a positive signal, as it indicates that insiders are financially interested in the company’s success.
This can also provide shareholders with greater transparency into the company’s operations and decision-making processes, as insiders are more likely to share information with shareholders who have a vested interest in the company’s success.
BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN) (CSE:BYND) ENTERS $62 BILLION MARKET WITH FILING OF US PROVISIONAL PATENT APPLICATION AND FULL SCALE PCT APPLICATION FOR ITS AI-CONNECTED EZ-G DEVICE (1)
Image Source (11)
On January 17, 2023, BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND)announced that in addition to the US Provisional Patent Application with serial number 63/297,009 that was filed on January 6, 2022, covering the monitoring and controlling aspects of its EZ-G device, the company filed a full-scale PCT application on January 5, 2023, under serial number PCT/IL2023/050016. (1)
The PCT application is based on BYND Cannasoft’s prototype of the EZ-G device that is currently under development and its operational aspects as a learning adult device. The PCT application further claims priority from the US Provisional application and covers an adult device with a structure and one or more moving and vibrating elements. (1)
In addition to potentially treating annoying phenomena in the female reproductive system, the EZ-G device includes technological advancements to provide a more sensual experience. The EZ-G device prototype uses sensors like a pressure sensor, temperature sensor, conductivity sensor, and heart rate sensor to determine what specifically enhances the users’ gratification.
Image Source (12)
The EZ-G device uses artificial intelligence (AI) to transmit and receive data from the device’s sensorson conditions of the user’s organs, such as moisture levels and pressure variations due to muscle contraction.
The EZ-G prototype includes a Bluetooth component for controlling the adult device via an app installed on a smartphone or other portable device to collect user information about preferences and generate custom programs.
The data collected from the sensors is uploaded to the secured cloud, where it is combined with other antonymic user preferences, including the actual duration of operation of the adult device, lubrication level, and the ideal vibration level.
This data enables the device to enhance the user’s overall experience, leading to heightened sensations and a more fulfilling encounter. By learning and adapting to the user’s preferences, the EZ-G device optimizes its performance to provide maximum sensual satisfaction.
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft said
“The EZ-G device has evolved to provide treatment relief from sensual and mental problems, including the ability to have intercourse as it relates to anxiety and physical pain. The device is capable of enhancing sensual gratification and reducing Dyspareunia by dispensing low concentrations of C-B-D oil lubricant in a controlled manner. It could be configured to use disposable capsules that include the C-B-D lubricant, which could be dispensed in accordance with data collected by the sensors. The sale of the disposable capsules containing the C-B-D lubricant would provide BYND Cannasoft with a revenue model much like the razor and the razor blade.” (1)
BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN)(CSE:BYND) EXPANDS FOOTHOLD IN THE MULTIBILLION-DOLLAR SEXTECH INDUSTRY WITH ITS NEXT AI-BASED TECHNOLOGY PATENT (23)
Image Source (21)
BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) is making its mark in the multibillion-dollar Sextech Industry as its subsidiary, Zigi Carmel Initiatives & Investments LTD., files a U.S. provisional patent application for an innovative smart female treatment device. This new device, powered by artificial intelligence (AI), aims to treat specific phenomena related to female sexual organs. (23)
The device leverages AI and machine learning algorithms to control its operational parameters based on the user’s physiological data. Its functions include stimulation of sexual organs according to user preferences, as well as real-time monitoring of user satisfaction levels through integrated sensors. The patent application covers an AI system that stores user preference data, allowing it to learn general and current operation preferences. By collecting data on responses to different operation parameters, the AI fine-tunes its operation to provide a personalized and optimized experience for each user.
In addition to its medical applications, BYND Cannasoft recognizes the potential of this AI-based device as a sex toy. The patented technology offers the ability to enhance the interaction between humans and machines, collecting data on user response to stimulation patterns, determining lubricant dispensing rates, and even identifying sexual climax using AI and machine learning techniques. The device ensures a natural and controlled experience based on real-time data and user preferences. It also includes a communication component that utilizes sensor data to create customized programs and upload data to the cloud.
Image Source (22)
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft, highlighted the significance of the AI-based device, especially in a time where companies are increasingly focusing on automated and personalized customer connections. Real-time technologies and generative AI are shaping consumer behavior and influencing purchasing decisions. BYND Cannasoft plans to secure the final registration of its patents, establish a robust marketing and sales system for both the AI-based device and the EZ-G device, and cater to both B2B and B2C sales. BYND Cannasoft Enterprises is poised to revolutionize the Sextech industry with its groundbreaking AI-based devices, bringing innovation, personalization, and enhanced user experiences to the forefront. (23)
MAJOR MILESTONE: BYND CANNASOFT ENTERPRISES (NASDAQ: BCAN) (CSE: BYND) COMPLETES LAB TESTING PHASE FOR INNOVATIVE EZ-G DEVICE (24)
Image Source (25)
BYND Cannasoft Enterprises (NASDAQ: BCAN) (CSE: BYND) has reached a significant milestone with the successful completion of the laboratory testing phase for its groundbreaking EZ-G device. The company, based in Ashkelon, Israel, and Vancouver, British Columbia, announced the accomplishment, highlighting the optimization of various sensors within the device. The EZ-G, a therapeutic solution powered by AI and machine learning, has shown promising potential in delivering low concentrations of C-B-D oils, including hemp seed oil and other natural oils, to address specific women’s health issues. (24)
During the laboratory testing phase, BYND Cannasoft conducted comprehensive experiments as part of the EZ-G device’s prototype development. The focus was on evaluating the functionality and performance of the integrated sensors, which detect indicators such as temperature, heart rate, contractions, and fluids. By collecting and analyzing data through accompanying software, the company utilized machine learning technology to optimize the device’s usage for users.
This milestone marks a significant achievement in the development of the EZ-G device, particularly in the successful functionality of its primary sensor, the capacitive sensor. The sensor has demonstrated its ability to accurately detect the presence or absence of liquid within the device, specifically identifying changes in fluid volume in the vagina. As a result, the device can regulate the flow of oil or lubricating fluid during operation without the need for manual intervention from the user.
With positive results from the laboratory testing phase, BYND Cannasoft is now poised to finalize the EZ-G prototype model and progress to the next phase of development: human trials involving focus groups of women across different age groups.
Yftah Ben Yaackov, CEO and Director of BYND Cannasoft, expressed enthusiasm about the successful completion of the laboratory testing phase for the EZ-G device. He emphasized the company’s commitment to leveraging advanced technology to enhance women’s health. Moving forward with human trials, Ben Yaackov believes the EZ-G device has the potential to revolutionize therapeutic approaches for women’s health issues.
BYND Cannasoft remains dedicated to ensuring that the EZ-G device meets the highest standards of safety, efficacy, and usability. Through continued research and development efforts, the company aims to make a meaningful contribution to women’s well-being by providing an innovative solution for targeted health concerns. (24)
BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN)(CSE:BYND)
TRENDS IN THE MARKET
Image Source (13)
Key Takeaways: (13)
Consumer demand is surging: There were 36m+ connected “intimate technology” devices in use globally last year, representing 87% YoY growth.
The market for connected devices alone is expected to more than double over the next 5 years to reach $9B.
Intimate Tech goes far beyond toys. It’s set to disrupt all areas of the sensual wellness space, from health to education.
The wider industry of sensual wellness, which is now worth $62B, is forecast to exceed $125B by 2026.
The sensual-health movement is driving change; industry veterans believe we are on the cusp of a surge in funding.
The US Intimate Technology market is still largely offline, leading to attractive ecommerce opportunities.
BYND CANNASOFT ENTERPRISES INC. (NASDAQ:BCAN)(CSE:BYND)
LET’S MEET THE TEAM LEADING THIS LITTLE-KNOWN “AI STOCK” INTO 2023 AND BEYOND. (14)
Image Source (15)
As a relatively new player in the adult toy market, BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) (CSE:BYND) has the advantage of being an early mover and can establish itself as a leader in the space.
Another advantage of BYND Cannasoft Enterprises Inc. is its experienced leadership team. The company is led by a team of experienced executives who have a proven track record of success in multiple industries. (14)
CLIENTS
MANAGEMENT
MOTI MARAM
President and Director
In 1986, together with a partner company, he founded a computer company that mainly provided services to EXATEC-compliant IBM AS 400 computers and subsequently sales and service to the first PCs in the world. After identifying a need for CRM and ERP software, Maram and his partner, Avner Tal, established a software company that manufactures CRM and ERP management software called BENEFIT in 2000.
HAROLD WOLKIN
Harold is a retired, former Investment Banker and Financial Analyst with over 40 years of business experience. An advisor to Chief Executive Officers and Board of Directors of both public and private companies. Strong financial expertise, a Chartered Financial Analyst (CFA) and member of the Institute of Corporate Directors.
YFTAH BEN YAACKOV
CEO and Director
Professional lawyer since 2004. Specialized in real estate related issues on all aspects of it including real estate corporations, complex sales transactions, real estate unions, real estate taxation. Notary License holder since 2014. Managed large projects of tens of thousands Square meters for a total amount of above 400 million NIS. At the last 5 years yftah has assembled the business activity of 2 of the largest medical cannabis company’s in Israel and has an enormous experience and knowledge in this field.
DR. STEFÁNIA SZABÓ
Director
Stefánia is the Vice President of Pace Law Firm and Director of International Relations at Pace Global Advantage in Toronto, Canada. She is a former diplomat, a charismatic government services, management and public relations professional with 25 years of progressive experience. She is an international lawyer by profession, and serves as member of the executive committee of the Canada-Israel Chamber of Commerce.
AVNER TAL
VP Sales & Marketing, CTO and Director
Technology director of Beyond Solution Company. I studied electronics and control. I served in the Navy and I was in the team that implemented and developed the technology and even carried out the experiments that included “smart” missiles. Joined Moti to established a computer company that supported Exatech computers and its innovative network.
NEWS
GlobeNewswire•2 days agoBYND CANNASOFT CLOSES US$2.6 MILLION UNDERWRITTEN PUBLIC OFFERINGASHKELON, Israel and VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately US$2.6 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 1,733,334 common shares at a price to the public of
GlobeNewswire•4 days agoBYND CANNASOFT ANNOUNCES PRICING OF US$2.6 MILLION UNDERWRITTEN PUBLIC OFFERINGASHKELON, Israel and VANCOUVER, British Columbia, July 17, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately US$2.6 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consists of 1,733,334 common shares at a price to th
GlobeNewswire•7 days agoBYND CANNASOFT ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERINGASHKELON, Israel and VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, o
GlobeNewswire•11 days agoBYND CANNASOFT ANNOUNCES SUCCESSFUL COMPLETION OF LABORATORY TESTING PHASE FOR EZ-G DEVICE OPTIMIZATIONASHKELON, Israel and VANCOUVER, British Columbia, July 10, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today the successful completion of the laboratory testing phase aimed at optimizing the various sensors in its innovative EZ-G device. The EZ-G device, a therapeutic solution utilizing AI and machine learning, has shown promise in releasing low concentrations of CBD oils, including hemp seed oil and other natu
GlobeNewswire•3 months agoBYND Cannasoft Subsidiary Zigi Carmel Initiatives & Investments LTD. filed U.S. Provisional Patent Application 63461609 on April 25, 2023 covering the mechanical structure, operation, and controlling aspects of a treatment device monitored by sensors and capable of stimulating the male sexual organs based on user preferences ASHKELON, Israel and VANCOUVER, British Columbia, April 27, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Com
GlobeNewswire•3 months agoBYND Cannasoft Subsidiary Zigi Carmel Initiatives & Investments LTD. received a positive opinion from the examiner of the PCT for its method that enables its AI-based device to identify a level of satisfaction according to parameters received from the device sensorsASHKELON, Israel and VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today it has received a positive opinion fro
GlobeNewswire•4 months agoPlans to formulate proprietary CBD oil and brand through a licensed grower in Israel for distribution outside of Israel in its AI based device and EZ-G deviceVANCOUVER, British Columbia and ASHKELON, Israel, March 14, 2023 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) today announced plans to formulate a proprietary CBD oil and brand through a licensed grower in Israel for distribution outside of Israel for its new artificial i
GlobeNewswire•4 months ago
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY ONE THOUSAND USD BY A THIRD PARTY, TD MEDIA LLC FOR A ONE DAY BCAN AWARENESS CAMPAIGN. PURSUANT TO AGREEMENT BETWEEN TD MEDIA LLC AND DEDICATED INVESTORS LLC. ON BEHALF OF BYND CANNASOFT, DEDICATED INVESTORS HAS BEEN HIRED FOR A PERIOD BEGINNING ON 7/24/2023 AND ENDING ON 7/24/2023. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
GlobeNewswire•2 days ago